Tumor =< 4 cm maximum diameter, including clinical stage IA and selected IB by positron emission therapy (PET)/computed tomography (CT) scan of the chest and upper abdomen performed within 90 days prior to randomization
Patients must have measurable disease; MRI and/or PET/CT scans need to be performed within 2 weeks prior to registration
Appropriate for protocol entry based upon the following minimum diagnostic workup:\r\n* History/physical examination including examination for encephalopathy, ascites, weight, height, and blood pressure within 14 days prior to study entry\r\n* Assessment by radiation oncologist and medical oncologist or hepatologist who specializes in treatment of HCC within 28 days prior to study entry\r\n* Pre-randomization scan (REQUIRED for all patients): Within 28 days prior to study entry, CT scan chest/abdomen/pelvis or positron emission tomography (PET) CT chest/abdomen/pelvis with multiphasic liver CT or multiphasic liver magnetic resonance (MR) scan (MRI of abdomen and pelvis with contrast with CT chest) is permitted
Absence of residual disease and absence of metastasis, as confirmed by a negative baseline computed tomography (CT) of the pelvis, abdomen, and chest no more than 4 weeks prior to randomization. Confirmation of disease-free status will be assessed by an independent central radiologic review of imaging data.
Baseline chest computed tomography (CT) with or without contrast must be performed within 6 months (180 days) prior to randomization to ensure no evidence of disease; if clinically indicated additional imaging studies must be performed to rule out metastatic disease
Investigations, including chest X-ray or computed tomography (CT) chest, bone scan (with radiographs of suspicious areas) and abdominal ultrasound or liver scan or CT abdomen have been performed between the first histologic diagnosis and the time of registration\r\n* Chest X-ray, 2 view (or chest CT, or positron emission tomography [PET]/CT) is required only if clinically indicated or recommended by National Comprehensive Cancer Network (NCCN) guidelines\r\n* Bone scans (with x-rays of abnormal areas) are required only if indicated or recommended by NCCN guidelines\r\n* Abdominal imaging is required only if clinically indicated or recommended by NCCN guidelines
Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the study if liver imaging (computed tomography [CT], magnetic resonance imaging [MRI], positron emission tomography [PET]-CT, or PET scan) performed within 90 days prior to randomization does not demonstrate metastatic disease and the requirements above are met
Patients with alkaline phosphatase that is > ULN but =< 2.5 x ULN or unexplained bone pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan performed within 90 days prior to randomization does not demonstrate metastatic disease
Clinical stage: T2N1, T3N0, T3N1\r\n* N2 disease is to be estimated as four or more lymph nodes that are >= 10 mm\r\n* Clinical staging should be estimated based on the combination of the following assessments: physical exam by the primary surgeon, computed tomography (CT) or positron emission tomography (PET)/CT scan of the chest/abdomen/pelvis and either a pelvic magnetic resonance imaging (MRI) or an ultrasound (endorectal ultrasound [ERUS]); if a pelvic MRI is performed, it is acceptable to perform CT of the chest/abdomen, omitting CT imaging of the pelvis
Patients must have measurable or non-measurable disease; patients must have a chest/abdominal/pelvis computed tomography (CT) scan (or positron emission tomography [PET]/CT of diagnostic quality, conventional or spiral) prior to registration; if the patient is unable to undergo CT with IV contrast due to allergy or renal insufficiency, a non-contrast CT may be performed; all scans needed for assessment of measurable disease must be performed within 28 days prior to registration; non-measurable disease must be assessed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form
Baseline chest computed tomography (CT) must be performed within 1 month (30 days) of randomization to ensure no evidence of disease; if clinically indicated, additional imaging studies must be performed to rule out metastatic disease
Contrast-enhanced computed tomography (CT) scans of the neck, chest, abdomen and pelvis are required; a whole body positron emission tomography (PET)/CT scan with diagnostic quality images and intravenous iodinated contrast may be used in lieu of a contrast enhanced CT of the neck, chest, abdomen and pelvis; contrast may be omitted if the treating investigator believes that exposure to contrast poses an excessive risk to the patient; patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; all measurable lesions must be assessed within 28 days prior to registration; tests to assess non-measurable disease must be performed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form (RECIST 1.1)
Patients must have measurable or non-measurable stage III/locally advanced or metastatic carcinoma of the breast where local therapy with curative intent is not possible; lesions must be evaluated =< 4 weeks prior to study randomization; diagnostic-quality computed tomography (CT) scans with both oral and intravenous (IV) contrast are the expected radiologic method, unless an alternative is approved\r\n* NOTE: Where baseline imaging has already been performed =< 6 weeks prior to study randomization, repeat imaging may not be required
Patient must have clinically T1-3, N1 breast cancer at the time of diagnosis (before neoadjuvant therapy); clinical axillary nodal involvement can be assessed by palpation, ultrasound, CT scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, or PET/CT scan
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; baseline measurements and evaluations of all sites of disease must be obtained within 4 weeks prior to randomization and must be acquired by multiphasic computed tomography (CT) or contrast magnetic resonance imaging (MRI)\r\n* NOTE: positron emission tomography (PET)-CT scans are allowed provided the CT portion of the exam is equivalent to a diagnostic CT scan and includes both oral and IV contrast
The patient must have the following assessments done =< 8 weeks prior to randomization:\r\n* Examination by a head and neck surgeon\r\n* Chest x-ray (or chest computed tomography [CT] scan or CT/positron emission tomography [PET] of the chest or magnetic resonance imaging [MRI]) to rule out distant metastatic disease
Patients with screening ALT/AST or ALP above institutional upper limit of normal should have liver ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) at any time point between diagnosis of current breast cancer and randomization; screening bone scan is required if ALP and/or corrected calcium level are above the institutional upper limit; (note positron emission tomography [PET]/CT scan may be used as an alternative imaging technique)
Evidence of metastatic breast cancer; patient considered at high risk of having disseminated disease (i.e. those with locally advanced disease, clinical N2-3 or pathological N1-3 with the exception of pN1a in adjuvant patients) should have a CT/MRI scan of the thorax/abdomen/pelvis or any other area as clinically indicated and a bone scan or a CT scan with bone windows at any point between diagnosis of the current breast cancer and randomization to rule out metastatic breast cancer; (note PET/CT scan may be used as an alternative imaging technique and precludes the need for bone scan); patients with screening ALT/AST or ALP above institutional upper limit of normal should have liver ultrasound, CT or MRI at any time point between diagnosis of current breast cancer and randomization; screening bone scan is required if ALP and/or corrected calcium level are above the institutional upper limit; (note PET CT scan may be used as an alternative imaging technique)
No evidence of bone metastases (M0) on bone scan within 120 days prior to registration (sodium fluoride [NaF] positron emission tomography [PET]/CT is an acceptable substitute)\r\n* Equivocal bone scan findings are allowed if plain films (or CT or magnetic resonance imaging [MRI]) are negative for metastasis
No lytic lesions on skeletal survey and whole body positron emission tomography (PET)/computed tomography (CT) other than a single lesion associated with solitary bone plasmacytoma
No lytic lesions on skeletal survey and whole body PET/CT other than a single lesion associated with solitary bone plasmacytoma within 28 days prior to registration
Patients must have a whole body or limited whole body PET/CT scan performed within 42 days prior to registration
All disease must be assessed and documented on the S1608 FDG-PET/CT assessment form
Patients must have no evidence of extrapelvic disease; complete workup staging should be performed prior to initiation of therapy to rule-out presence of metastatic disease; this should include: computed tomography (CT) scan of the thorax with IV contrast, as well as a CT of the pelvis and abdomen with IV and oral (PO) contrast performed using multi-detector CT and equal or less than 5 mm slice thickness; if the patient is unable to tolerate contrast, then magnetic resonance imaging (MRI) with IV gadolinium should be performed; a chest x-ray should be done first, and if abnormal, then a CT scan of the chest should be done
Any pT-stage based on American Joint Committee on Cancer 7th edition eligible; study entry will be based on the following diagnostic workup:\r\n* History/physical examination within 60 days prior to step 1 registration\r\n* Negative distant metastatic workup: \r\n** A computed tomography (CT) scan of the abdomen and pelvis (with contrast [CT without contrast is permitted if the patient is not a candidate for contrast, i.e., renal function or allergy]) or magnetic resonance imaging (MRI) of the pelvis within 120 days prior to step 1 registration; (Please note: Lymph nodes will be considered negative (NO)if they are =< 1.5 cm short axis);\r\n** Bone scan within 120 days prior to step 1 registration; (please note: a sodium fluoride [NaF] positron emission tomography [PET]/CT is an acceptable substitute and if the bone scan is suspicious, a plain x-ray, CT scan, NaF PET/CT and/or MRI must be obtained to rule out metastasis)
Documentation by positron emission tomography(PET)/computed tomography (CT) scan, CT scan, or magnetic resonance imaging (MRI) that the patient has untreated measurable metastatic disease per RECIST 1.1
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination by a radiation oncologist (and a surgeon if surgery is planned) within 30 days prior to registration\r\n* Imaging proof of limited metastatic disease and response to therapy/stable disease, by at least diagnostic quality computed tomography (CT) chest through the adrenals or positron emission tomography (PET)/CT, within 30 days prior to registration.
Contrast-enhanced computed tomography (CT) scans of the chest, abdomen and pelvis are required; a whole body positron emission tomography (PET)/CT scan with diagnostic quality images and intravenous iodinated contrast may be used in lieu of a contrast enhanced CT of the chest, abdomen and pelvis; imaging of the head and neck is required only if the patient has a head/neck primary; contrast may be omitted if the treating investigator believes that exposure to contrast poses an excessive risk to the patient; if skin lesions are being followed as measurable disease, photograph with a ruler included and physician measurements, must be kept in the patient’s chart as source documentation; all measurable lesions must be assessed within 28 days prior to registration; tests to assess non-measurable disease must be performed within 42 days prior to registration; all disease must be assessed and documented on the baseline tumor assessment form (RECIST 1.1)
Stage II-IVB disease (American Joint Committee on Cancer [AJCC], 7th edition [ed.]) with no evidence of distant metastasis, based upon the following minimum diagnostic workup:\r\n* History/physical examination by a Medical Oncologist or Clinical Oncologist or Radiation Oncologist or Ear, Nose, Throat specialist (ENT), which must include an endoscopic evaluation, a complete list of current medications, and assessment of weight and weight loss in the past 6 months within 21 days prior to registration\r\n* Evaluation of tumor extent with one of the following combinations required within 28 days prior to registration:\r\n** Magnetic resonance imaging (MRI) of the nasopharynx and neck; or computed tomography (CT) of the nasopharynx and neck with =< 3 mm contiguous slices with contrast and bone windows (to evaluate base of skull involvement). \r\n** MRI of the nasopharynx and positron emission tomography (PET)/CT (with contrast) of the neck\r\n*** Note: If a treatment planning CT scan is used, it must be with =< 3 mm contiguous slices with contrast and be read by a radiologist\r\n* To rule out distant metastasis, patients must undergo the following imaging within 28 days prior to registration:\r\n** A CT scan with contrast of the chest and abdomen (required), and the pelvis (optional), or a total body PET/CT scan (non-contrast PET/CT is acceptable)\r\n** A bone scan only when there is suspicion of bone metastases (a PET/CT scan can substitute for the bone scan)
Pathologic stage T3-4 or N1-3 or T1-2, N0 with a close (=< 1 mm) or microscopically positive surgical margin (American Joint Committee on Cancer [AJCC], 7th edition); patients must be free of distant metastases based upon the following minimum diagnostic workup:\r\n* History/physical examination within 8 weeks prior to registration\r\n* Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to registration; at a minimum, contrast computed tomography (CT) imaging of the chest is required; positron emission tomography (PET)/CT is acceptable
Patients must have undergone radical hysterectomy (open, laparoscopically or robotic) and staging including pelvic node sampling or dissection for cervical carcinoma within 70 days prior to study entry (NOTE: if the patient did not have a para-aortic lymph node sampling/dissection, but had common iliac node dissection that was negative, a positron emission tomography [PET]-computed tomography [CT] is recommended, but not required; a negative pre or post-operative PET scan or PET-CT scan of the para–aortic nodes is required if the patient did not undergo para-aortic or common iliac nodal sampling/dissection)
No distant metastases, based upon the following minimum diagnostic workup (NOTE: patients with positive para-aortic nodes- completely resected, PET/CT negative are eligible):\r\n* History/physical examination within 56 days prior to study entry\r\n* Contrast-enhanced imaging of the abdomen and pelvis by either CT, magnetic resonance imaging (MRI), or whole body PET-CT (with or without contrast) within 90 days prior to registration (NOTE: whole body PET-CT is preferred) \r\n* Chest x-ray (posterioranterior [PA] and lateral) or chest CT within 70 days prior to study entry (except for those who have had whole body PET-CT)
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination within 60 days prior to registration\r\n* Clinical grade computed tomography (CT) scans of the chest, abdomen, and pelvis with radionuclide bone scan OR whole body positron emission tomography (PET)/CT within 60 days prior to study registration
Patient must have computed tomography (CT) chest/abdomen/pelvis with contrast or fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/CT scan performed within 28 days prior to step 1 registration
Patient must have a CT of chest/abdomen with contrast or FDG-PET/CT scan within 28 days prior to step 2 registration; patients must not have evidence of progression per RECIST 1.1 or modified RECIST for pleural tumors
Patient must have a CT of chest/abdomen/pelvis with contrast or FDG-PET/CT scan within 28 days prior to step 3 registration; patient must not have evidence of progression per RECIST 1.1 or modified RECIST for pleural tumors
The following imaging workup to document metastases within 45 days prior to study registration are required: CT scans of the chest, abdomen and pelvis with radionuclide bone scan OR whole body (at least skullbase to midthigh) positron emission tomography (PET)/CT
Measurable disease >= 1.5 cm seen on computed tomography (CT) scan and fludeoxyglucose F-18 (FDG) avid disease on positron emission tomography (PET) scan
Patients with current and symptomatic pneumonitis, or extensive bilateral lung disease on high resolution CT scan
Subjects must have measurable or evaluable disease:\r\n* Evaluable disease must be evidenced by computed tomography (CT) or positron emission tomography (PET) scans (abnormal PET scans may be used as long as the CT portion is of diagnostic quality)\r\n* Subject must have at least one objective measurable disease parameter:\r\n** Measurable disease on cross sectional imaging that is >= 2 cm in the longest diameter and measurable in 2 perpendicular dimensions\r\n** Splenomegaly > 13 cm in cranio-caudal dimension as measured by CT
No evidence of metastatic cancer on imaging including a bone scan and computed tomography (CT) scan of chest/abdomen/pelvis
Patients must be clinically staged according to the 7th edition (2010) of the American Joint Committee on Cancer (AJCC) staging system and must have either clinical T3-4a, or >= N1 disease; staging should include upper endoscopy with endoscopic ultrasound and a fludeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) scan (with diagnostic CT abdomen/pelvis preferred)
Patients with evidence of extramedullary disease at diagnosis will have computed tomography (CT) scan of the chest, abdomen and pelvis to obtain baseline values within 28 days prior to registration
Chest imaging =< 3 months of enrollment, including computed tomography (CT)-scan or chest x-ray
No evidence of metastases based on radiological imaging (computed tomography [CT], MRI or positron emission tomography [PET]/CT including chest abdomen and pelvis)
Measurable, 18F-deoxyglucose (FDG)-avid (Deauville score ? 3) systemic disease (using Lugano Classification response criteria) by positron emission tomography (PET)-diagnostic computed tomography (CT). For subjects with treated central nervous system (CNS) disease, a head CT and/or brain/spinal magnetic resonance imaging (MRI) as clinically appropriate will be required to follow CNS disease response per Lugano Classification response criteria.
A baseline computed tomography (CT) chest/abdomen/pelvis and bone scan or positron emission tomography (PET)/CT
Subjects may have completed concurrent chemoradiation with a standard chemotherapy regimen (cisplatin/etoposide, carboplatin/paclitaxel or cisplatin/pemetrexed [non-squamous only]) and a dose of radiation ranging from 59.4-66.6 Gy; subjects must have stable disease or disease response as evidenced on computed tomography (CT) or positron emission tomography (PET) scan evaluation; for those eligible, protocol therapy should begin a minimum of 28 days and a maximum 56 days following the completion of chemoradiation\r\nOR\r\nSubjects may have completed up to 2 cycles of consolidation therapy started within 4 weeks of completion of radiation; after completion of consolidation chemotherapy, subjects must have stable disease or disease response as evidenced by CT or PET scan evaluation; for those eligible, protocol therapy should begin 3-4 weeks after the last cycle of chemotherapy
Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to treatment; at a minimum, chest x-ray is required; computed tomography (CT) imaging of the chest or positron emission tomography (PET/CT) is acceptable
Achieved at least stable disease to salvage treatment determined by positron emission tomography (PET)/computed tomography (CT) using 2014 Lugano Classification prior to ASCT
There must be documentation by PET/CT scan, CT scan, or MRI, that the patient has evidence of measurable metastatic disease per RECIST 1.1.
Metastasis that is > 10 mm in longest dimension or exhibits radiotracer uptake consistent with metastasis on positron emission tomography/computed tomography (PET/CT)
A baseline computed tomography (CT) chest/abdomen/pelvis and bone scan or positron emission tomography (PET)/CT
Positron emission tomography (PET)/CT scan including neck, chest, abdomen, pelvis within 4 weeks of study enrollment documenting the absence of distant metastases
Pathologically (histologically or cytologically) proven diagnosis of solid malignancy\r\n* NOTE: fludeoxyglucose F 18 (FDG)-positron emission tomography (PET) scans are required for full staging of metastatic disease prior to enrollment; if subject has had an FDG-PET/computed tomography (CT) scan within the last 8 weeks, it will not need to be repeated\r\n* NOTE: pathological confirmation is not required for all disease sites as long as the sites of metastatic disease are radiographically and clinically consistent with metastatic disease from a known (biopsy proven) primary\r\n* NOTE: biopsy does not have to be performed at the time of enrollment for patients with recurrent disease as long as biopsy was performed at time of initial diagnosis
Pathologically (histologically or cytologically) proven diagnosis of solid malignancy within 8 weeks of registration\r\n* NOTE: fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed tomography (CT) scans are required for full staging of metastatic disease; if subject has had an FDG-PET/CT scan within the last 8 weeks, it will not need to be repeated\r\n* NOTE: pathological confirmation is not required for all disease sites as long as the sites of metastatic disease are radiographically and clinically consistent with metastatic disease from a known (biopsy proven) primary\r\n* NOTE: the primary site does not have to be the site of pathological confirmation; for example, in a patient with a radiographic lung lesion with mediastinal lymphadenopathy and a liver lesion, a liver biopsy which is constant with lung primary would preclude the necessity for further pathologic diagnosis
Patients unable to have an FDG-PET/CT scan, either through insurance coverage, patient decision or other reason are not eligible for this study
Measurable disease (at least 1 lesion of >= 1.5 cm in one diameter) as detected by computed tomography (CT) or the CT images of the positron emission tomography (PET)/CT (PET/CT fusion); skins lesions can be used if the area is greater than or equal to 2 cm in at least one diameter and photographed with a ruler
Histologic or cytologically confirmed diagnosis of uveal melanoma with measurable disease (based on RECIST 1.1 criteria) in the liver (by CT, PET/CT or MRI) at the time of screening.
Patients must have measurable disease by computed tomography (CT) or positron emission tomography (PET) scan, with one or more sites of disease >= 1.5 cm in longest dimension
Patients with AST or ALT or alkaline phosphatase > ULN are eligible for inclusion in the study if liver imaging (CT, MRI, PET-CT, or PET scan) performed within 28 days prior to randomization does not demonstrate metastatic disease and the requirements in criterion (just above) are met.
Patients with alkaline phosphatase that is > ULN but less than or equal to 2.5 x ULN or with unexplained bone pain are eligible for inclusion in the study if bone imaging (bone scan, PET-CT scan, or PET scan) performed within 28 days prior to randomization does not demonstrate metastatic disease.
Patients with N2 or N3 nodal disease or T3 primary disease must undergo liver and bone imaging (as described in 4.1.13 and 4.1.14) within 28 days prior to randomization, irrespective of baseline lab results, and studies must not demonstrate metastatic disease. Chest imaging with chest x-ray PA and Lateral, CT of the chest, or PET-CT must also be performed.
Tany N1-3 or T3-4 N0 as determined by endoscopic ultrasound (EUS) and PET/CT; all palpable or CT/PET visible lymph nodes outside the usual surgical field must be biopsy-proven negative for cancer
All patients must have initial PET/CT scans to document no evidence of metastatic or unresectable squamous cell cancer
T1-2 N0 as determined by EUS and PET/CT
Stage at presentation: cT2-cT4, cN0-cN3, cM0
Measurable disease of at least 1.5 cm on computed tomography (CT) or positron emission tomography (PET)-CT scan
Scans used to determine eligibility (CT scan of the chest/abdomen/pelvis and liver) must be performed within 28 days prior to initiation of Induction Phase treatment.
Metastatic disease identified via radiographic assessment by computed tomography (CT) scans of the chest, abdomen, pelvis, and nuclear bone scan; magnetic resonance imaging (MRI) may be used if deemed necessary by the investigator; more specifically, patients must have at least one of the following at time of study enrollment:\r\n* Any visceral metastases identified by CT scans or MRI\r\n* Site(s) of bony metastasis identified by nuclear bone scan, MRI, and/or CT scan\r\n* Lymph node based disease not considered to be within a single radiation therapy port (e.g. at or above the aortic bifurcation)
Stage II/III disease as per American Joint Committee on Cancer (AJCC) staging 7.0\r\n* Baseline imaging with standard of care fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) scan and endoscopic ultrasound within 28 days prior to registration
No definitive evidence of metastases on screening CT or MRI of abdomen/pelvis and radionuclide whole body bone scan per the judgment of the investigator. Abdominal and/or pelvic lymph nodes measuring 2 cm or less in short axis diameter are allowed. Lesions identified on other imaging modalities (e.g. PSMA or choline PET) that are not visualized on CT and/or MRI or radionuclide bone scan are allowed. Equivocal lesions on bone scan should be followed up with additional imaging as clinically indicated.
Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:\r\n* History/physical examination within 30 days prior to registration including resting heart rate;\r\n* Fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed tomography (CT) scan for staging within 60 days prior to registration\r\n* Magnetic resonance imaging (MRI) scan with contrast of the brain (preferred) or CT scan of the brain with contrast within 60 days prior to registration; \r\n* Forced expiratory volume in one second (FEV1) >= 0.8 liter or >= 35% predicted with or without bronchodilator within 90 days prior to registration;\r\n** Patients who meet the criterion above without oxygen (O2), but who need acute (started within 10 days prior to registration) supplemental oxygen due to tumor-caused obstruction/hypoxia are eligible, provided the amount of the O2 needed has been stable
Must have at least one lesion that is > 15 mm (1.5 cm) in the longest diameter and avid by Fluoro Deoxy Glucose (FDG) Positron Emission Tomography (PET) scan
Patient has one or more metastatic tumors evaluable by CT scan with contrast (or MRI, if patient is allergic to CT contrast media) per RECIST 1.1. Imaging investigations including CT/MRI of chest/abdomen/pelvis or other scans as necessary to document all sites of disease must be performed within 14 days prior to randomization. Qualifying scans performed as part of standard of care prior to patient signature of the study informed consent will be acceptable as baseline scanning as long as scanning is performed < 14 days prior to randomization.
?1 bone lesion identifiable by radiograph, computed tomography (CT), positron emission tomography - computed tomography (PET-CT), or magnetic resonance imaging (MRI).
The tumor is ? 3 cm in size and clearly observable in computerized tomography (CT scan)
Absence of distant metastases on standard diagnostic work-up =< 16 weeks prior to registration; (chest computed tomography [CT], chest x-ray [CXR], or positron emission tomography [PET]/CT)
Patients must have staging scans with abdominal/pelvic computed tomography (CT) or magnetic resonance imaging (MRI) scan, and CT scan or x-ray of the chest within 56 days prior to registration; if the alkaline phosphatase is > 1.5 x upper limit of normal (ULN), there is a presence of suspicious bone pain, or if there is other clinical suspicion of bone metastases, a whole body bone scan is required within 56 days prior to registration
Patients who cannot undergo neither MRI nor computed tomography (CT) evaluation/examination
Fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET) and measurable disease of at least 1.5 cm in minimum dimension by computed tomography (CT) scan with contrast, as assessed by the site radiologist
Patients must have measurable or evaluable disease that is FDG avid with standardized uptake value (SUV) > 3 on PET/CT
Prior to chemotherapy +/- or thoracic radiotherapy, patients must be defined as limited-stage or extensive-stage SCLC after clinical staging evaluation involving the following:\r\n* History/physical examination;\r\n* Computed tomography (CT) of the chest and abdomen with contrast (does not have to be done if the patient has had a positron emission tomography (PET)/CT scan prior to initiating chemotherapy or thoracic radiotherapy)\r\n* MRI of the brain with contrast or diagnostic head CT with contrast\r\n* For patients without evidence of extensive-stage SCLC on chest and abdomen CT and brain MRI or head CT, a PET/CT or bone scan is required to confirm limited-stage SCLC
Measurable or evaluable disease, including at least one of the following: measureable tumor by CT or MRI; a positive MIBG, or PET scan; positive bone marrow biopsy/aspirate.
Evidence of metastatic disease on imaging studies (computed tomography [CT] and/or bone scan)
Patients with measurable disease defined as at least one of the following:\r\n* For patients with extramedullary disease (EMD) measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) or the CT portion of the positron emission tomography (PET)/CT: must have at least one lesion that has a single diameter of >= 2 cm; skin lesions can be used if the area is >= 2 cm in at least one diameter and measured with a ruler\r\n* Plasma cell count >= 0.5 X 10^9/L or 5 percent of the peripheral blood white cells\r\n* Plasma cell count if determined by flow cytometry, >= 200/150,000 events
Patients must have prior CT scan images available for investigators to collect
Detectable disease by at least one of the following modalities: computed tomography (CT), positron emission tomography (PET), bone scan, or magnetic resonance imaging (MRI)
Non-secretors must have measurable disease such as plasmacytomas, or positron emission tomography (PET) avid lytic lesions or bone marrow plasmacytosis >= 30% at the time of relapse to be eligible
Bulky metastases, defined as any tumor nodule or lymph nodes > 5 cm in greatest dimension on axial images on pre-treatment CT, PET/CT, or magnetic resonance imaging (MRI)\r\n* Note: patients with bulky (> 5 cm) disease for whom gross total cytoreduction is deemed feasible by a surgeon (with confirmation by a second surgeon after radiologic review) are eligible for participation in the context of cytoreductive surgery
Stage D0 disease with documented biochemical progression documented by rising PSA and no evidence of metastatic disease by physical examination, computed tomography (CT) scan or bone scan
Measurable disease (at least 1 lesion of >= 1.5 cm in diameter) as detected by CT or the CT images of the PET/CT; NOTE: patients with Waldenstrom macroglobulinemia are not required to have measurable disease by CT or PET/CT if monoclonal protein is detectable by serum protein electrophoresis and/or immunoglobulin M (IgM) level is at least 2 times upper limit of normal
CLL diagnosis confirmed as have biopsy –proven Richter’s transformation; NOTE: both untreated and previously treated patients in this category can be enrolled as long as measurable disease can be detected by PET/CT or CT (>=1.5 cm in diameter)
Measurable disease that has not been previously irradiated on computed tomography (CT) scans of at least 2 cm, OR if the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation; imaging must be completed no greater than 6 weeks prior to study enrollment
PET/CT-guided cryoablation criteria-cohort 2:\r\n* Patients must have a mass that is well visualized under PET/CT; tumors that are not clearly seen by MRI but showing on PET/CT will be ablated with PET/CT guidance
PET/CT-guided cryoablation exclusion criteria-cohort 2:\r\n* PET/CT is contraindicated in the pregnant patient\r\n* Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PET/CT guidance
Patient has one or more metastatic tumors measurable per RECIST 1.1 by CT scan ?4 weeks prior to entry into the study
Appropriate diagnostic/staging workup, including:\r\n* Complete history and physical examination\r\n* Whole body PET/computed tomography (CT) scan within 42 days prior to study entry demonstrating hypermetabolic pulmonary lesion(s) and/or thoracic lymph node(s), with a maximum standardized uptake volume (SUV) > 6 for at least one lesion; if PET/CT was obtained more than 42 days prior to study entry and is not repeated, CT scan of the chest within 28 days prior to study entry demonstrating stable disease is required\r\n* Magnetic resonance imaging (MRI) of the brain or CT scan of the head with contrast within 42 days prior to study entry\r\n* Biopsy confirmation of suspected metastatic disease identified by PET/CT is recommended\r\n* Pulmonary function tests (PFTs) within 6 weeks of study entry are highly recommended but not required
Evidence of distant metastasis on upright chest x-ray (CXR), computed tomography (CT) or other staging studies
Stage III A or B disease, including no distant metastases- based on following diagnostic workup:\r\n* History/physical examination prior to registration\r\n* Computed tomography (CT) scan of the chest or positron emission tomography (PET) scan within 28 days of study entry\r\n* CT scan of abdomen or magnetic resonance imaging (MRI) of abdomen or PET scan within 28 days of study entry\r\n* An MRI of the brain or head CT scan with contrast within 28 days of study entry\r\n* Total body PET scan within 28 days of study entry\r\n* Mediastinoscopies are highly recommended
Patients with muscle-invasive (i.e. T2, T3, T4), locally advanced non-resectable, or metastatic urothelial carcinoma as assessed on baseline radiographic imaging obtained within 28 days prior to study registration; the required radiographic imaging includes:\r\n* Abdomen/Pelvis – computed tomography (CT) scan\r\n* Chest – chest x-ray or CT scan
Absence of lytic bone lesion on X-ray, computed tomography (CT), or positron emission tomography (PET)/CT and not more than 1 lesion on spinal magnetic resonance imaging (MRI) (NOTE: at the discretion of the investigator, PET/CT may replace MRI in patients who have a contraindication to MRI)
Positron emission tomography (PET) scan is suggested for a PSA >= 0.2 ngs/ml
Clinical stage T1N0, T2N0, T3N0; high risk T1 and low risk T3 stage patients are also allowed. Clinical staging should be estimated based on the combination of the following assessments: physical exam by the primary surgeon, computed tomography (CT) chest/abdomen/pelvis or positron-emission tomography (PET)/CT along with pelvic MRI and endoscopic rectal ultrasound (ERUS). If a pelvic MRI is performed, it is acceptable to perform CT of the chest/abdomen, omitting CT imaging of the pelvis.
No clinical evidence of metastatic spread; staging should include endoscopic ultrasound and positron emission tomography (PET)/computed tomography (CT) as recommended by National Comprehensive Cancer Network (NCCN) guidelines; PET/CT should be performed within 3 weeks of signing informed consent
Have no evidence of distant metastases (as determined by endoscopic ultrasound [EUS], PET-computed tomography (CT) or staging laparoscopy
Staged by positron emission tomography (PET)/computed tomography (CT) and esophagogastroduodenoscopy (EGD) OR CT without (w/) contrast and EGD to have stage II or III disease; endoscopic ultrasound (EUS) is encouraged but not required
Measurable disease, meaning at least 1 lymph node or other lymphomatous lesion with a long axis of ? 1.5 cm by computed tomography (CT) imaging, and at least one fluorodeoxyglucose (FDG)-avid lesion by FDG-positron emission tomography (PET) scan
If solitary lesion, metastasis confirmed with either biopsy or two independent imaging modalities (i.e. CT and PET [positron emission tomography], bone scan and MRI, modality at the discretion of the treating physician)
Metastatic prostate cancer (M1) as documented by appropriate medical imaging (i.e. computed tomography [CT]-scan, positron emission tomography [PET] scan or bone scan)
Creatinine =< 2.5 (within 14 days of PET imaging)
Patient must have a least one lesion greater than 2 cm on standard imaging (CT, MR, octreotide, or dotatate imaging) that is judged amenable to AMT-PET
Patients must have measurable disease > 1.5 cm evidenced by computed tomography (CT) scan of the neck/chest/abdomen (abd)/pelvis or CT/positron emission tomography (PET) scans
Cohort B1\r\n* Newly diagnosed low-volume metastatic disease with either:\r\n** Bone metastases as documented by radionuclide bone scan amenable to treatment with a maximum of 3 radiation isocenters* (note: a patient will be considered eligible if entering the study with a positive positron emission tomography (PET) scan without restriction to the number of isocenters and otherwise meets eligibility requirements) And/Or\r\n** Retroperitoneal nodes up to the level of the renal hilum with/without pelvic nodal metastasis < 1.5 cm in the short axis OR
Patients must have a clinical T stage documented by the treating urologist/medical oncologist within 90 days prior to treatment start using the seventh (7th) edition American Joint Committee on Cancer (AJCC) staging system, recorded as the urologist’s/medical oncologist’s best clinical assessment of extent of local disease by digital rectal examination and available imaging studies such as transrectal ultrasound, computed tomography (CT) scan, and/or MRI
Positron emission tomography (PET)-computed tomography (CT) within the last 60 days showing radiographic stage I to IIIa lung cancer (mediastinal staging biopsy is allowed but not required)
Stage IIIB, or distant metastases (including malignant pleural effusion) identified on PET-CT scan or biopsy (PET abnormalities that are negative for malignancy on biopsy will be considered on a case by case basis
The patient has a biopsy-proven radio-opaque (visible by computed tomography [CT]) lung cancer or secondary metastasis to the lung.
Locoregional lymph node metastases are permitted but patients with distant metastases are ineligible; imaging to evaluate for distant metastases should consist of a minimum of computed tomography (CT)/magnetic resonance imaging (MRI) of abdomen/pelvis or CT urogram and a chest x-ray (CXR) or CT chest; patients for which there is clinical suspicion or symptoms of bone metastasis should have a bone scan completed to rule out metastatic disease prior to enrollment on study
Metastatic disease by bone scan or other nodal or visceral lesions on CT or MRI at any time (past or present).
To be eligible for randomization, patients must: \r\n* Meet all the inclusion criteria;\r\n* Have no progression of disease after 6-12 weeks of osimertinib per RECIST 1.1. (To assess for progressive disease patients must have the following imaging: \r\n** Either a positron emission tomography (PET)/computed tomography (CT) scan or a CT scan of the chest/abdomen/pelvis (or CT chest) ** A CT scan or a magnetic resonance imaging (MRI) of the brain);\r\n* Have target lesions (lesions that will be treated with LCT if the patient is randomized to that arm). Patients that have a complete response (CR) to front-line osimertinib (e.g. no visible disease to target) will continue to be followed for progression on study but will not be randomized
Patients with systemic T cell lymphoma of any stage and any subtypes; patient must have had at least one standard chemotherapy and measurable disease at the time of enrollment; bidimensional measurable disease of at least 1.5 cm in the greatest transverse diameter as documented by computed tomography (CT) or positron emission tomography (PET)/CT
Patients must have systemic cross-sectional imaging (positron emission tomography [PET]/computed tomography [CT] or CT of chest, abdomen, and pelvis) which shows no evidence of metastatic disease
Locally advanced or metastatic disease not amenable to surgery with curative intent with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigator based on an assessment of all known disease sites by computerized tomography (CT) scan or magnetic resonance imaging (MRI) of chest/abdomen/pelvis within 28 days before the first dose of cabozantinib. In patients with intravenous (IV) contrast allergy or borderline renal function, CT without IV contrast or 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) CT may be used as clinically indicated.
Stage M1\r\n* Metastatic disease can be documented by bone scan or computed tomography (CT) scan or magnetic resonance imaging (MRI) or positron emission tomography (PET)/CT or the combination of these tests
Metastatic disease as evidenced by soft tissue and/or bony metastases on baseline bone scan and/or computed tomography (CT) scan of the chest, abdomen, and pelvis
Staging positron emission tomography (PET)/computed tomography (CT) (invasive mediastinal staging strongly encouraged but not required)
Patients must have a tissue diagnosis of diffuse large B cell lymphoma, with a negative positron emission tomography (PET)/computed tomography (CT) scan performed within 28 days of study enrollment, with one of the following clinical features: \r\n* High risk international prognostic index (IPI)\r\n* Activated B-cell–like (ABC)-subtype DLBCL\r\n* Double hit/ triple hit DLBCL
Patient must have known pathologic diagnosis of diffuse large B cell lymphoma (DLBCL), and evidence of persistent disease on PET/CT or CT.
Patients who cannot undergo MRI or single-photon emission computed tomography (SPECT)/computed tomography (CT)
Measurable disease that can be accurately measured in at least one dimension as >= 2.0 cm with computed tomography (CT), ultrasound, or magnetic resonance imaging (MRI) techniques; extranodal disease that is measurable by fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) imaging only will also be allowed; note that if an excisional biopsy was performed that removed the sole site of measurable disease, the patient will not be eligible for leukapheresis and generation of CAR T cell product
Measurable lesion; patients are required to have at least one measurable non-bone lesion ? 10 mm that has not been irradiated\r\n* Measurable metastatic disease documented by radiograph, computed tomography (CT) scan, positron emission tomography (PET)/CT, magnetic resonance imaging (MRI), or physical exam is required; each subject will be required to have at least one measurable lesion that has not been irradiated with a minimum size in at least one diameter of ? 10 mm for liver lesions, lung, skin, and ? 15 mm lymph node metastases; biopsy of recurrent site(s) is not required
Positron emission tomography-computed tomography (PET-CT) (preferred) or a CT of chest, abdomen, and pelvis within 60 days of registration showing radiographic stage II to IVB nasopharyngeal cancer
Patients must have measurable disease, defined as tumor mass which is > 10 mm with spiral CT scan or MRI. Baseline imaging scan must be within 8 weeks of registration.
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination within 28 days prior to registration;\r\n* Computed tomography (CT) imaging of the chest, abdomen and pelvis within 28 days prior to registration documenting disease consistent with FIGO stage Ill or IV disease (patients who cannot receive contrast may instead undergo magnetic resonance imaging [MRI] of abdomen and pelvis along with non-contrast chest CT);
Bone marrow involvement based on PET/CT scan at screening
Patients must have evaluable disease by clinical exam (i.e. palpable lymphadenopathy, measurable skin lesions, etc.), laboratory assessment (i.e. lymphoma involvement of bone marrow or peripheral blood by morphology, cytology or flow cytometry), and/or imaging (measurable lymph nodes or masses on computed tomography [CT] or magnetic resonance imaging [MRI] and/or evaluable fludeoxyglucose [FDG]-avid lesions on positron emission tomography [PET])\r\n* NOTE: lesions that have been irradiated cannot be included in the tumor assessment unless unequivocal tumor progression has been documented in these lesions after radiation therapy
For Arm G, patients with disease beyond the pelvis, including but not limited to the para-aortic nodes as determined by positron emission tomography (PET)/CT will be excluded.
Positron emission tomography (PET)-computed tomography (CT) within the last 45 days showing radiographic stage I to IIIa lung cancer (mediastinal staging biopsy is allowed but not required)
One of the following combinations of imaging is required within 8 weeks of registration:\r\n* Or a computed tomography (CT) scan of the neck (with contrast) and a positron emission tomography (PET)/CT of neck and chest (with or without contrast)\r\n* Or an magnetic resonance imagining (MRI) of the neck (with contrast) and a PET/CT of neck and chest (with or without contrast)\r\n* Note: A CT scan of the neck and/or a PET/CT performed for the purposes of radiation planning may serve as both staging and planning tools
Tumor imaging and bone marrow evaluation for histologic analysis of marrow tumor cell quantity must be obtained within 4 weeks (28 days) prior to enrollment onto study; patients must have ONE of the following:\r\n* Measurable tumor on magnetic resonance imaging (MRI), computed tomography (CT), or x-ray; measurable is defined as minimum of 20 mm in at least one dimension; for patients who are in first response (i.e., those patients with persistent sites of tumor after frontline therapy but who have never relapsed), a biopsy of a lesion or bone marrow must demonstrate viable neuroblastoma cells or patients must have a lesion positive on iobenguane (MIBG) scan or positron emission tomography (PET) scan; if the lesion was irradiated, the MIBG scan, PET scan or biopsy must be done at least 4 weeks after radiation is completed\r\n* MIBG or PET scan with positive uptake at minimum of one site; if lesion was radiated, the scan must be done at least 4 weeks after radiation completed\r\n* Bone marrow with tumor cells seen on routine morphology of bilateral aspirate and/or biopsy on at least one bone marrow sample
Pretreatment computed tomography (CT) chest /abdomen /pelvis within 28 days of protocol enrollment
All patients should have measurable disease; measurable disease is defined as a lymph node or tumor mass that is >= 1.5 cm in at least one dimension by computed tomography (CT) or the CT portion of the PET/CT
Patients must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive metaiodobenzylguanidine [MIBG] or positron emission tomography [PET] scans) or measurable (computed tomography [CT], magnetic resonance imaging [MRI]) disease documented after completion of prior systemic therapy
Has had restaging imaging after initiation of immunotherapy, at least 4 weeks after pre-immunotherapy baseline imaging; computed tomography (CT) or positron emission tomography (PET)/CT of at least chest/upper abdomen must be performed within 4 weeks prior to registration; for patients with history of brain metastases, brain magnetic resonance imaging (MRI) or CT is required within 4 weeks of registration; for other patients brain MRI or CT is required within 12 weeks of registration; diagnostic PET/CT performed as part of radiation simulation can be used as the restaging imaging
Surgically resectable (T1-3 Nx by endoscopic ultrasound); excluded are:\r\n* Very early stage tumors (T1N0)\r\n* Cervical esophageal tumors\r\n* Tumors invading the tracheobronchial tree or associated with tracheoesophageal fistula\r\n* Any evidence of distant metastases (as determined by endoscopic ultrasound [EUS] or computed tomography/positron emission tomography [CT/PET])\r\n* Cervical, supraclavicular, or other nodal disease that is either not included in the radiation field or is not able to be resected at the time of esophagectomy
Extensive bilateral lung disease on high-resolution computed tomography (HRCT) scan
The patient is staged with endoscopic ultrasound (EUS)/esophago-gastro-duodenoscopy (EGD) and positron emission tomography (PET)/computed tomography (CT) scan
Patients must have demonstrated evidence of increasing contrast enhancement on MR or computed tomography (CT) imaging while on stable or increasing dose of steroid
Unequivocal evidence of metastatic disease defined by computerized tomography (CT) (includes resectable metastases)
Have measurable disease by computed tomography (CT) or positron emission tomography (PET) scan, with one or more sites of disease >= 1.5 cm in longest dimension
Clinically stage I disease by American Joint Committee on Cancer (AJCC) 7th edition (N0, M0, T stages T1-T2a) or patients with stage T2bN0M0 disease (clinical stage IIA), as determined by a computed tomography (CT) chest, abdomen, pelvis or a positron emission tomography (PET) CT =< 60 days of treatment start, who are medically unfit for standard of care chemotherapy as documented by a medical oncologist or radiation oncologist, or who refuse standard of care chemotherapy as documented by a medical oncologist or radiation oncologist
Unresectable stage 2-3 non-small cell lung cancer (based on computed tomography/positron emission tomography [CT/PET], magnetic resonance imaging [MRI] or CT of brain, and physical exam);\r\n* Eligible if recurrence after surgery and now has the equivalent stage 2-3 non-small cell lung cancer (NSCLC) OR had sub totally resected stage 2-3 NSCLC
Disease evaluable by computed tomography (CT) or positron emission tomography (PET) imaging
A PET/CT scan is required within 12 weeks (plus/minus 1 week) of study registration. Any lymph node suspected of harboring disease based on its shape, size, or PET standardized uptake value (SUV) should be discussed by treating physician and diagnostic radiologist
The following mandatory staging studies must be done within 12 weeks before study registration:\r\n* PET/CT scans of both lungs, the mediastinum, adrenal glands and rest of the body; primary tumor dimension will be measured on diagnostic CT and again on simulation CT using the lung window setting\r\n* Mediastinoscopy or endobronchial ultrasound -guided biopsy of the mediastinal lymph nodes is recommended and required for any patients with PET/CT or CT findings suggesting lymph node involvement\r\n* Brain magnetic resonance imaging (MRI) or CT scan if symptoms or signs suggest brain metastases\r\n* Invasive mediastinal staging: For all patients with CT or PET evidence of hilar involvement (level 10) or with mediastinal lymph nodes > 1.0 cm in the shortest diameter or clinically suspicious by treating physician and/or radiologist, disease must be staged by cervical mediastinoscopy, esophageal endoscopic ultrasound-guided biopsy, or endobronchial ultrasound-guided biopsy
Cutaneous metastases diagnosis confirmed prior to consent by preferred institutional methodology which may include, but is not limited to: biopsy ? 3 months; conventional radiography; imaging techniques to include bone scan (scintigraphy), computed tomography (CT), fluorodeoxyglucose-positron emission tomography (FDG-PET)/CT), magnetic resonance imaging (MRI), F-fluoromisonidazole-(F-FMISO) PET/CT, fluorothymidine-(FLT) PET/CT, fluoroestradiol-(FES) PET/CT, and PET/MRI;
Staging by positron emission tomography (PET)-computed tomography (CT) scan (required) and magnetic resonance imaging (MRI) brain (if clinically indicated) showing no evidence of metastatic disease (mediastinoscopy is not required unless imaging is indeterminate and is then considered standard of care)
Neck computed tomography (CT) and/or neck magnetic resonance imaging (MRI), and whole body positron emission tomography (PET)-CT
Inability to undergo PET-CT
Staging computed tomography (CT) chest, abdomen, pelvis (CAP) or positron emission tomography (PET)/CT shows no evidence of metastatic disease
Patients are required to have computed tomography (CT) neck and chest or positron emission tomography (PET)/CT and have no documented evidence of distant metastases
No radiographic evidence of metastatic disease by computed tomography (CT) scan and bone scan, performed within the prior 4 weeks
Measurable nodal disease by computed tomography (CT)
Positive 68Ga-PSMA-11 PET/CT (positron emission computed tomography ) or diagnostic 177Lu-PSMA-617 scintigraphy
Subject who are willing to undergo a bone marrow aspiration and biopsy and computed tomography (CT) scan for disease burden assessment
Patients must have measurable disease, defined as at least one lesion that is > 15 mm (1.5 cm) in the longest axis on cross-sectional imaging and measureable in two perpendicular dimensions per computed tomography (spiral computed tomography [CT]), positron emission tomography (PET)-CT or magnetic resonance imaging (MRI)
>= 1 lesion detectable on CT, MRI, fludeoxyglucose F-18 (18FDG) PET-CT, or PET-MRI
Stage II-IV disease; participant will need measurable disease by computed tomography (CT) or positron emission tomography (PET) scans if enrolled in the dose-expansion cohort
Patients with Stage IV breast cancer are not eligible; baseline staging to document absence of metastatic disease is not required, however is recommended as determined by institutional practice (in patients where there may be a reasonable suspicion of advanced disease e.g., large tumors, clinically positive axillary lymph nodes, signs and symptoms); if performed, reports of these examinations must be available; examination type for staging, i.e. X-ray, sonography, bone scans, computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET)-CT, is at the discretion of the investigator
Participants must have shown unequivocal evidence for tumor progression by MRI or computed tomography (CT) scan
Patients must have measurable disease > 1.5 cm evidenced by computed tomography (CT) scan of the neck/chest/abdomen/pelvis or CT/positron emission tomography (PET) scans
Patient must have measurable disease > 1.5 cm evidenced by computed tomography (CT) of the neck/chest/abdomen (abd)/pelvis or CT/positron emission tomography (PET) scans
Pathologically confirmed diagnosis of relapsed or refractory B-cell acute lymphoblastic leukemia/lymphoma with measurable bone marrow lymphoblasts or biopsy-proven extramedullary site measurable by computed tomography (CT) or positron emission tomography (PET)/CT imaging; Philadelphia chromosome-positive (Ph+) B-ALL patients must have failed treatment with at least one second generation tyrosine kinase inhibitor; prior allo-HCT is allowed
Metastatic disease radiographically documented by CT or bone scan
MRI of the pelvis or positron emission tomography (PET)-CT within 4 months before registration
Radiographically measurable disease by computed tomography (CT) scan, defined as at least one node > 1.5 cm in size or assessable disease
Evidence of progressive disease by imaging modalities or biopsy - persistent positron emission tomography (PET) activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of computed tomography (CT) changes indicating progression
Measurable disease on computed tomography (CT) scan of thorax, abdomen, and pelvis per RECIST v1.1 criteria
Unable to receive iv contrast for required CT scans
Measurable disease that has not been previously irradiated on positron emission tomography-computed tomography (PET-CT), or computed tomography (CT), of at least 1.5 cm within the last 21 days before the start of IP treatment.
Evidence of myeloma defining events or biomarkers of malignancy due to underlying plasma cell proliferative disorder meeting at least ONE of the following: \r\n* 1. Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the upper limit of normal or > 2.75 mmol/L (> 11 mg/dL) \r\n* 2. Renal insufficiency: creatinine clearance < 50 ml/min or serum creatinine > 2 mg/dL \r\n* 3. Anemia: hemoglobin value < 10 g/dL or 2 g/dL < normal reference \r\n* 4. Bone lesions: one or more osteolytic lesions on skeletal radiography, computerized tomography (CT) or 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography CT (PET-CT) \r\n* 5. Clonal bone marrow plasma cell percentage >= 60% \r\n* 6. Involved: uninvolved serum free light chain ratio >= 100 measured by freelite assay\r\n* 7. > 1 focal lesions on magnetic resonance imaging (MRI) studies (each focal lesion must be 5 mm or more in size)
Patients must not have evidence of metastatic disease per positron emission tomography (PET)/ computed tomography (CT) scan; mediastinal lymph node involvement is acceptable
The treated lesion must be within 2 cm of the abdominal gastrointestinal tract (abdominal esophagus to sigmoid colon) on the basis of cross sectional imaging study such as computed tomography (CT), positron emission tomography (PET)/CT, or MRI
Presence of radiographically measurable disease (defined as the presence of a >= 1.0 cm lesion, as measured in the longest dimension by computed tomography [CT] scan or positron emission tomography [PET]/CT scan or magnetic resonance imaging [MRI] scan)
Have undergone a second-look surgery by a MD Anderson Gynecologic Oncology faculty after having achieved a complete clinical response to frontline surgery and adjuvant chemotherapy as evidenced by\r\n* Normal physical exam,\r\n* Normal computed tomography (CT) or positron emission tomography (PET)-CT of abdomen and pelvis or other equivalent imaging, and\r\n* Normalization of CA125 (< 35 U/mL)
Disease that is measurable where:\r\n* A non-nodal lesion is considered measurable if its longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with computed tomography (CT) scan, CT component of a positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI)\r\n* A malignant lymph node is considered measurable if its short axis is >= 1.5 cm when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm); Note: tumor lesions in a previously irradiated area are not considered measurable disease; Note: disease that is measurable by physical examination only is not eligible
Patients with locally advanced unresectable or metastatic urothelial carcinoma as assessed on baseline radiographic imaging obtained within 28 days prior to study registration; the required radiographic imaging includes:\r\n* Abdomen/Pelvis – computed tomography (CT) scan\r\n* Chest – chest x-ray or CT scan
Distant metastases, based upon:\r\n* CT scan or MRI of the abdomen/pelvis within 120 days prior to registration and\r\n* Bone scan within 120 days prior to registration; if the bone scan is suspicious, a plain x-ray and/or MRI must be obtained to rule out metastasis prior to registration
Metastatic breast cancer not amenable to potentially curative surgery; patients must have disease that is measurable and/or non-measurable as defined by RECIST 1.1 criteria (assessed by computed tomography [CT] scan chest/abdomen/pelvis with contrast or fludeoxyglucose [FDG] positron emission tomography [PET]-CT scan obtained within 4 weeks of registration)
Measurable disease that has not been previously irradiated on positron emission tomography-computed tomography (PET-CT) of at least 1.5 cm
No splenomegaly ?16 cm by CT scan.
Patients must have had radiographic evidence of tumor progression by brain MRI or computed tomography (CT) scan with contrast
Subjects with more than one site of distant metastatic disease (beyond the head and neck) as evidenced by computed tomography (CT) scan or positron emission tomography (PET)/CT or biopsy\r\n* A subject with a single lung nodule (deemed cancerous by PET/CT or biopsy) will not be excluded
Evidence of diverticulitis at baseline, including evidence limited to computed tomography (CT) scan only
Bone marrow involvement based on CT or PET scan at screening
Presence of measurable disease by computed tomography (CT) scan
Patients must have measurable disease > 1.5 cm evidenced by computed tomography (CT) scan of the neck/chest/abdomen (abd)/pelvis or CT/positron emission tomography (PET) scans
Low-volume lung metastases are defined as solid pulmonary nodules < 2 cm with non-spiculated contours, no benign-appearing calcifications, and =< 14 in number, diagnosed by computed tomography of the chest or positron emission tomography (PET)
Patients will undergo CT imaging of the chest, abdomen, and pelvis to evaluate lung and liver metastases within 30 days of registration; for patients who cannot tolerate CT contrast or have hepatic steatosis that reduces the sensitivity of CT, MRI of the liver will be performed
Baseline imaging with an fludeoxyglucose (FDG)-positron emission tomography (PET) scan negative for distant metastatic disease must be obtained =< 28 days prior to registration
Surgically resectable (T2N0, T3N0, Tany with node positivity, M0), as determined by endoscopic ultrasound (EUS) and the following minimum diagnostic work-up:\r\n* Whole-body PET/computed tomography (CT) (PET/CT of skull base to mid-thigh is acceptable)\r\n* EUS =< 21 days prior to registration\r\n* NOTE: Patients may have regional adenopathy including para-esophageal, gastric, gastrohepatic and celiac nodes; if celiac adenopathy is present, it must be < 2 cm\r\n* NOTE: If patient unable to have PET/CT then CT chest/abdomen/pelvis with contrast (preferred) or MRI chest/abdomen/pelvis with contrast
Uncontrolled diabetes (i.e., will interfere with the performance of the FDG PET/CT scans)
Fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET) and dimensional measurable disease of at least 1.5 cm as documented by radiographic technique (spiral computed tomography [CT] preferred)
Evidence of progressive disease by imaging modalities or biopsy - persistent positron emission tomography (PET) activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of computed tomography (CT) changes indicating progression
pre-operative imaging (chest CT and PET-CT
Detectable positron emission tomography (PET)-positive disease
INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Patients must have measurable disease by at least one of the criteria below:\r\n* Extra skeletal disease that can be accurately measured in at least one dimension as >= 10 mm with conventional computed tomography (CT) techniques as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\r\n* Skeletal or bone-only disease measurable by fludeoxyglucose F 18 (FDG) positron emission tomography (PET) imaging
Disease status requirement: Measurable disease defined as the presence of ? 1 nodal lesion that measures ? 1.5 cm in a single dimension as assessed by X-ray Computed Tomography (CT) (Positron Emission Tomography (PET/CT), or magnetic resonance imaging [MRI]
Have baseline imaging within 6 weeks of enrollment (computed tomography [CT], magnetic resonance [MR] or positron emission tomography [PET]/CT imaging) and have measurable disease on physical examination or imaging studies; any lesion >= 1.5 cm in long axis dimension is considered measurable
Patients must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive metaiodobenzylguanidine [MIBG] or positron emission tomography [PET] scans) or measurable (computed tomography [CT], magnetic resonance imaging MRI]) disease documented after completion of prior systemic therapy
No evidence of metastases other than regional lymphadenopathy as assessed by imaging of the chest, abdomen and pelvis with CT of the chest and CT or MRI of the abdomen; regional lymph nodes, per 7th edition American Joint Committee on Cancer (AJCC) staging manual (2010) for kidney cancer, include the following positions: renal hilar, precaval, paracaval, retrocaval, interaortocaval, paraaortic, preaortic, and retroaortic
Any MPM histology (epithelial, mixed, sarcomatoid)\r\n* N0 or N1 nodal disease as present on preoperative chest computed tomography (CT) and/or positron emission tomography (PET)-CT\r\n* N2 nodule disease if no progression after 2 cycles of standard chemotherapy; progression will be considered if additional N1 or N2 disease develop during chemotherapy
Patients must have at least one bi-dimensionally measurable lesion by palpation, clinical exam, or radiographic imaging within 6 weeks of the start of study intervention (X-ray, computed tomography [CT] scan, positron emission tomography [PET] scan, magnetic resonance imaging [MRI], or ultrasound)
Pathologic confirmation of NSCLC diagnosis is recommended whenever possible; this will generally be accomplished using computed tomography (CT) guided or bronchoscopic biopsies; if pathologic confirmation is not possible, a target lesion must be a non calcified pulmonary nodule that is present on at least 2 imaging studies (can include simulation scan); the nodule must have increased in size or proportion of solid component on CT and/or show increased fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) over at least 2 imaging studies
The presence of metastatic disease amenable to computed tomography (CT) or ultrasound guided biopsy; this may include thoracolumbar vertebral bodies, pelvis, femur or humerus or soft tissue or nodal metastasis amenable to biopsy (excluding lung or pleural lesions)
Have measurable nodal disease, including at least 1 disease site measuring 1.5 cm in longest dimension on computed tomography (CT) or fludeoxyglucose (FDG)-positron emission tomography (PET)
Measurable disease (at least 1 lesion >= 1.5 cm in diameter) as detected by PET/CT
No evidence of metastasis on staging computed tomography (CT) scans of the chest, abdomen and pelvis
Patients must receive a magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET) of the brain within 6 months of signing informed consent; if new central nervous system (CNS) lesions are present, patient must have definitive treatment (including surgery or radiation); principal investigator (PI) or his designee should make final determination regarding enrollment
Metastatic disease as evidenced by the presence of soft tissue and/or bone metastases on imaging studies (CT of abdomen/pelvis, bone scintigraphy)
Progressive disease while receiving androgen deprivation therapy defined by any one of the following as per the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) bone scan criteria or Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 during or after completing last therapy:\r\n* PSA: at least two consecutive rises in serum PSA, obtained at a minimum of 1-week intervals, with the final value >= 2.0 ng/mL\r\n* Measurable disease: >= 50% increase in the sum of the cross products of all measurable lesions or the development of new measurable lesions; the short axis of a target lymph node must be at least 15 mm by spiral CT to be considered a target lesion\r\n* Non-measurable (bone) disease: the appearance of two or more new areas of uptake on bone scan (or NaF PET/CT) consistent with metastatic disease compared to previous imaging during castration therapy; the increased uptake of pre-existing lesions on bone scan will not be taken to constitute progression, and ambiguous results must be confirmed by other imaging modalities (e.g. X-ray, CT or magnetic resonance imaging [MRI])
Patients must be willing to undergo FLT PET/CT or NaF PET/CT scans for the investigational component of this trial and have no known allergies to FLT or NaF
Patients must have metabolically active (positron emission tomography [PET] scan positive) measurable disease (defined as lesions greater than 1.5 cm long axis that can be accurately measured in two dimensions by computed tomography [CT])
Subjects must be able to undergo either MRI or computed tomography (CT)
Subject has no evidence of disease based on radiographical imaging\r\n* Subject was deemed to have a complete objective response at completion of primary platinum-based chemotherapy by computed tomography (CT) scan and cancer antigen (CA)-125
Subjects who have minimal CT scan findings suspicious of residual disease are eligible provided there is no evidence of progression of disease by Rustin Criteria, defined as: \r\n* Present CT Scan findings show no change from CT Scan at baseline, and\r\n* Current CA-125 is below institutional upper normal limit and remains unchanged upon two consecutive measurements at least one week apart, and\r\n* CA-125 was above institutional upper normal limit at diagnosis
No distant metastases, based on the following workup within 60 days prior to registration\r\n* Magnetic resonance imaging (MRI) of the pelvis or computed tomography (CT) abdomen/pelvis (A/P)\r\n* Bone scan or sodium fluoride positron emission tomography (PET), that if suspicious has MRI or plain X-rays to rule out bone metastasis
Patients must have documentation of relapse that includes either doubling of CA125 serum levels confirmed by measurements greater than one week apart or identification of a new measurable lesion greater than 1 cm in the peritoneal cavity either by computed tomography/magnetic resonance imaging (CT/MRI), positron emission tomography (PET)/CT scan or physical exam (expanding pockets of ascites fluid that may serve as an alternative source of tumor cells) if the index lesion is not accessible for biopsy for vaccine formulation; recurrence outside the peritoneal cavity will be accessed using standard Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Patients should have bi-dimensional measurable disease using the Cheson criteria (measureable disease by computed tomography [CT] scan defined as at least 1 lesion that measures >= 1.5 cm in single dimension)
All patients must be staged with a physical exam, computed tomography (CT) of the chest and contrast-enhanced helical thin-cut abdominal CT; unresectability is defined by CT criteria: \r\n* Evidence of tumor extension to the celiac axis or superior mesenteric (SM) artery, or \r\n* Evidence on either CT or angiogram of occlusion of the SM vein or SM/portal vein confluence
The subject has documented worsening of disease (progressive disease) at screening compared with a previous computed tomography (CT) scan or magnetic resonance imaging (MRI) image done within 14 months of screening documentation of progression may be made by radiological (CT, MRI, or positron emission tomography [PET]), clinical or serological  assessment; if documentation is radiological, screening scan be compared to any previous scan (CT, MRI or PET) within 14 months of cycle 1 day 1 (C1D1)
The patient should not have direct evidence of regional or distant metastases after appropriate staging studies, including no distant metastases (M0) on bone scan within 90 days of study enrollment; equivocal bone scan findings are allowed if plain films are negative for metastasis; positron emission tomography (PET) or prostate specific membrane antigen (PSMA) scans can be performed instead of a bone scan
Visceral metastases as assessed by abdominal or pelvic computed tomography (CT) or other imaging modality
No evidence of bone metastases (M0) on bone scan, only for PSA > 20 or Gleason >= 8, (sodium fluoride [NaF] positron emission tomography [PET]/CT is an acceptable substitute) performed no more than 120 days prior to registration; equivocal bone scan findings are allowed if plain films and/or MRI are negative for definite metastases
Radiographically measurable or clinically evaluable disease by computed tomography (CT) scan of chest/abdomen/pelvis with and without contrast =< 28 days prior to registration
Computed tomography of the chest, abdomen, and pelvis (CT CAP) and bone scan performed within 30 days prior to study entry and does not demonstrate metastatic disease
Patient must have had a diagnosis of high risk NB at initial diagnosis or if non-high risk at time of initial diagnosis must have had evidence of metastatic progression when > 18 months of age\r\n* Patient must have measurable or evaluable disease occurring as one of the following:\r\n** Disease progression after initiation of upfront NB therapy defined as:\r\n*** New disease site documented on MIBG scintigraphy; or computed tomography (CT)/magnetic resonance imaging (MRI); or any new bone site that is fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) avid (in patient known to have MIBG non-avid tumor) AND has MRI findings consistent with tumor OR has a biopsy showing NB or ganglioneuroblastoma\r\n*** Greater than 20% increase in a least one dimension of soft tissue mass documented by CT/MRI AND a minimum absolute increase of 5 mm in longest dimension in existing lesions\r\n*** Bone marrow biopsy meeting revised International Neuroblastoma Response Criteria (INRC) criteria for progressive disease\r\n** Refractory disease such that response to upfront therapy (defined as at least 4 cycles of multi-agent induction chemotherapy) is less than partial response\r\n** Persistence of disease after at least a partial response to frontline therapy (i.e. patient has had at least a partial response to frontline therapy but still has residual disease by MIBG scan, CT/MRI, or bone marrow aspirate/biopsies); patients in this category are REQUIRED to have histologic confirmation of viable NB from at least one residual site; tumor seen on routine bone marrow morphology is sufficient
Assessment of all known disease sites, eg, by CT scan, MRI, bone scan as appropriate, and/or FDG-PET scan within 28 days before the first dose of cabozantinib
No distant metastases, based upon:\r\n* CT scan or MRI of the pelvis within 120 days prior to registration\r\n* Bone scan within 120 days prior to registration; if the bone scan is suspicious, a plain x-ray and/or MRI must be obtained to rule out metastasis
Patients must have primary tumor =< 10 cm as defined by computed tomography (CT) largest axial dimension
Within 60 days of registration: patients must have fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)-CT scan (or CT chest/abdomen/pelvis with IV contrast), and magnetic resonance imaging (MRI) brain with IV contrast (preferred) or CT scan of the brain with contrast; non-contrast MRI scans of the chest/abdomen/pelvis or brain are permitted for workup if patient has allergy to CT contrast or renal insufficiency
Measurable disease by CT or magnetic resonance imaging (MRI) or the CT portion of the PET/CT: must have at least one lesion that has a single diameter of >= 2 cm
Patients must have measurable disease defined as lesions that can be accurately measured in two dimensions by computed tomography (CT), magnetic resonance imaging (MRI), medical photograph (skin or oral lesion), plain x-ray, or other conventional technique and a greatest transverse diameter of 1 cm or greater; or palpable lesions with both diameters >= 2 cm; further, at least 1 of these lesions must be positive by positron emission tomography (PET) scan (i.e., Deauville score of 4 or more); Note: CT scans remain the standard for evaluation of nodal disease
Patients must have a CT of chest, abdomen, and pelvis with PET within 28 days of enrollment; patients with evidence of lymphadenopathy in the neck must have a dedicated CT of neck
Patients must have a positron emission tomography (PET) scan within 56 days of enrollment
No distant metastasis by positron emission tomography (PET)/computed tomography (CT); PET/CT will be done at time of simulation in the treatment position
Measurable tumor on MRI or CT scan or X-ray
Measurable or evaluable disease, including at least one of the following: Measureable tumor by CT or MRI; or A positive MIBG or PET scan; or Positive bone marrow biopsy/aspirate.
The subject has had an assessment of all extracranial disease sites (e.g., by computerized tomography (CT) scan, positron emission tomography-CT, and bone scan as appropriate) within 28 days before the first dose of cabozantinib
Resectable pancreatic adenocarcinoma disease as defined as follows:\r\n* No evidence of extrapancreatic disease by cross sectional imaging, PET scan, or laparoscopy, including nodal involvement beyond the peripancreatic tissues and/or distant metastases;\r\n* No evidence of tumor extension to superior mesenteric artery, hepatic artery, celiac axis, aorta, or inferior vena cava, and no evidence of occlusion or encasement of the superior mesenteric vein or superior mesenteric vein/portal vein confluence, as assessed by computed tomography (CT) using pancreatic protocol (or magnetic resonance imaging [MRI] in patients who cannot undergo CT) and EUS
Uncontrolled infections, defined as positive blood cultures within 72 hours of study entry, or evidence of progressive infection by imaging studies such as chest computed tomography (CT) scan within 14 days of registration
Measurable or assessable disease is required; measurable tumor size (at least one node measuring 2.25 cm^2 in bidimensional measurement) per computed tomography (CT) scan, other radiological study, and/or physical exam
Patients must receive a magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET) of the brain within 6 months of signing informed consent; if new lesions are present, patient must have definitive treatment; principal investigator (PI) or his designee should make final determination regarding enrollment (Turnstile I)
MRI/CT/PET of the brain within 30 days of lymphodepletion (Turnstile II)
Clinical T-stage (prior to systemic therapy, if applicable) >= T3a and/or positive lymph nodes by transurethral resection of bladder tumor (TURBT)/magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET)-CT or
New progressive pulmonary infiltrates on screening chest x-ray or chest computed tomography (CT) scan that have not been evaluated with bronchoscopy; infiltrates attributed to infection must be stable/improving after 1 week of appropriate therapy (4 weeks for presumed or proven fungal infections)
Patients must have measurable disease; baseline measurements and evaluations must be obtained within 4 weeks of registration to the study; abnormal positron emission tomography (PET) scans will not constitute evaluable disease unless verified by a diagnostic quality computed tomography (CT) scan; patients must use the same imaging modality (CT or PET/CT) throughout the study
RANDOMIZED PHASE II (ARMS K AND L): Patients must have measurable disease; baseline measurements and evaluations must be obtained within 4 weeks of registration to the study; abnormal PET scans will not constitute evaluable disease unless verified by a diagnostic quality CT scan; patients must use the same imaging modality (CT or PET/CT) throughout the study
cT2 N+ or cT3-T4 N0 or N+ as assessed by endorectal ultrasound (US)
The target lumpectomy cavity must be clearly delineated and the target lumpectomy cavity/whole breast reference volume must be =< 30% based on the postoperative/pre-enrollment computed tomography (CT) scan
Subjects must be diagnosed with either oropharyngeal or supraglottic squamous cell carcinoma\r\n* Primary tumor staging at T1, T2, or T3 based on contrasted neck computed tomography (CT), complete physical exam, and direct laryngoscopy; if possible, a positron emission tomography (PET) CT should also be collected; regardless of size, primary tumors must be mobile on physical exam and must not exhibit invasion of parapharyngeal fat on CT\r\n* Regional nodal metastases stages as N0, N1, or N2 without extracapsular spread (ECS)\r\n** N2a immediately eligible\r\n** N2b and N2c eligible when nodes are isolated (i.e., no conglomerate nodal masses)\r\n* No evidence of distant metastatic disease
Radiographic evidence of metastatic disease documented with bone scan or computed tomography (CT) scan\r\n* Patients with any number of metastatic site are allowed to enroll; however, only up to six sites will be selected for stereotactic body radiation therapy (SBRT) treatment, at the discretion of the treating radiation oncologist
Inability to tolerate contrast dye for baseline CT imaging
Histologically confirmed adenocarcinoma of the pancreas or ampulla of Vater; at least the majority of the histopathologic specimen must be identified as adenocarcinoma as opposed to another histologic subtype\r\n* If histological confirmation of adenocarcinoma cannot be obtained by biopsy, the following procedures may be employed:\r\n** Attempt a repeat biopsy to obtain a diagnosis\r\n** Present the case at John Hopkins University (JHU) tumor board and if the candidate has one of the following: a rising cancer antigen (CA) 19-9 or radiographic evidence of recurrence on magnetic resonance imaging (MRI), computed tomography (CT), and/or positron emission tomography (PET) scan then the patient can be considered for treatment on protocol\r\n* However, if these objectives cannot be met, the patient will not be a candidate
Patients must receive a magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET) of the brain within 6 months of signing informed consent; if new lesions are present, patient must have definitive treatment; principal investigator (PI) or his designee should make final determination regarding enrollment (Turnstile I)
MRI/CT/PET of the brain within 30 days of lymphodepletion
Bone marrow involvement based on computed tomography (CT) or PET scan at screening
History of severe reaction to contrast-enhanced computed tomography (CT) scan
Participants must have no clinical, radiographic, or laboratory evidence of cancer dissemination to the peritoneal cavity, chest cavity, or spread via hematogenous dissemination; computed tomography (CT) or positron emission tomography (PET)/CT of the chest, abdomen and pelvis must have been obtained within 10 weeks of study entry; there must be no measurable (macroscopic) disease within the radiation target volume following hysterectomy and lymphadenectomy
History of uveal melanoma and documented metastatic disease with at least one measurable lesion is required; which is >= 1 cm x 1 cm (on spiral computed tomography [CT] or equivalent)
Para-aortic nodal involvement above the level of the common iliac nodes or L3/L4 (if biopsy proven, PET positive or > 15mm short axis diameter on CT)
Locally advanced high-risk carcinoma of the uterine cervix, i.e.: intact cervix (i.e. non-operative) with International Federation of Gynecology and Obstetrics (FIGO) stage at least IB2 OR post-hysterectomy with either: residual gross disease or para-aortic nodal involvement (either resected or unresected) based upon standard diagnostic workup, including:\r\n* History/physical examination \r\n* Examination under anesthesia (if indicated)\r\n* Biopsy \r\n* Intravenous pyelogram and/or cystoscopy (if indicated)\r\n* Colonoscopy, sigmoidoscopy, or rigid proctoscopy (if indicated)\r\n* Posteroanterior (PA) and lateral chest x-ray or chest computed tomography (CT)\r\n* CT or magnetic resonance imaging (MRI) of the pelvis\r\n* Positron emission tomography (PET), PET/CT, or PET/CT simulation (encouraged)
Relapse/persistent disease evidenced by a computed tomography and fluorodeoxyglucose (FDG)-positron emission tomography (PET), or bone marrow biopsy
Fludeoxyglucose F 18 (FDG)-avid disease by FDG-PET/CT and measurable disease of at least 1.5 cm by CT
No distant metastases, based upon the following minimum diagnostic workup:\r\n* History and physical exam including a detailed description of the location, size and stage of the sarcoma, within 10 weeks prior to study entry\r\n* CT or magnetic resonance imaging (MRI) with contrast of the abdomen and pelvis within 8 weeks prior to study entry; the maximal dimension of the primary tumor will be measured in CT and MRI images; and\r\n* CT scan of the chest within 8 weeks prior to study entry
Participants with multifocal disease, lymph node or distant metastases; Note: multiple pulmonary nodules < 8 mm without a histological diagnosis detected incidentally in a non-screening CT scan may not be a basis for study exclusion because of the sensitivity/specificity of the CT scans of the chest/abdomen/pelvis
Able to undergo diagnostic PET/computed tomography (CT) or PET/CT simulation
Evidence of distant metastasis on upright chest x-ray (CXR), computed tomography (CT) or other staging studies
Clinical stage II and III NSCLC based on American Joint Committee on Cancer (AJCC) Cancer Staging Manual, seventh edition; acceptable imaging modalities to document nodal positivity include computed tomography (CT) chest, positron emission tomography (PET)-CT, or thoracic magnetic resonance imaging (MRI)
The target lumpectomy cavity must be clearly delineated and the target lumpectomy cavity/whole breast reference volume must be less than or equal to 30% based on the postoperative/pre-enrollment computed tomography (CT) scan
A radiation planning computed tomography (CT) scan which demonstrates a target lumpectomy cavity that is not clearly delineated or a target lumpectomy cavity/whole breast reference volume > 30%
No evidence of distant metastatic disease as documented by magnetic resonance imaging (MRI) of the brain and positron emission tomography (PET)/computed tomography (CT)
Patients must receive an magnetic resonance imaging (MRI)/computed tomography (CT) of the brain or positron emission tomography (PET)/CT within 6 months of consenting; if new lesions are present, principal investigator (PI) or his designee should make final determination regarding enrollment (Turnstile I)
MRI/CT of brain within 42 days of lymphodepletion; CT scan of chest/abdomen/pelvis or PET/CT within 30 days of lymphodepletion; Exception: patients randomized to receive dendritic cells may have an MRI of the brain within 30 days of lymphodepletion (Turnstile II-Chemotherapy/Cell Infusion-Inclusion Criteria)
Patients are eligible for transplantation if there is no evidence of progressive disease by imaging modalities or biopsy; persistent positron emission tomography (PET) activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of computed tomography (CT) changes indicating progression
No space occupying lesion on computed tomography (CT) scan of the liver i.e. normal CT scan post-resection; small lesion in the liver after resection can be ablated by alcohol injection or radio frequency ablation and can make patient eligible
Known incompatibility to CT or PET scans.
Patients with solid tumors must have measurable or evaluable (for neuroblastoma and Ewing sarcoma) disease. Tumor assessment will be done via computed tomography (CT), magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT). Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, may be considered measurable if there has been demonstrated progression in the lesion. Bone scans (if clinically indicated) should be obtained within ? 4 weeks prior to the start of treatment.
Measurable disease:\r\n* For nodal or extranodal disease (lymphoma or breast): must have at least 2 lesions that are >= 20 mm (2.0 cm) in the longest diameter by physical exam and/or on cross-sectional imaging and measurable in two perpendicular dimensions per computed tomography PET-computed tomography (CT), that are amenable to intralesional injections as determined by interventional radiology (including tumors that can be safely accessed using imaging guidance and treated with minimal risk to adjacent structures)\r\n* For cutaneous lesions (lymphoma or breast): at least two visible, non-infected skin lesions that are greater than 1 cm and are amenable to intralesional injection
Systemic corticosteroids between pre-PET and post-PET evaluation and biopsy
Measurable or assessable disease: measurable disease is defined as measurable by computed tomography (CT) (dedicated CT or the CT portion of a positron emission tomography [PET]/CT) or magnetic resonance imaging (MRI): to be considered measurable, there must be at least one lesion that has a single diameter of >= 1.5 cm \r\n* NOTE: Skin lesions can be used if the area is >= 1.5 cm in at least one diameter and photographed with a ruler; patients with assessable disease by PET are also eligible as long as the assessable disease is biopsy proven lymphoma
Evidence of progressive disease by imaging modalities or biopsy-persistent positron emission tomography (PET) activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of computed tomography (CT) changes indicating progression
Staging evaluation within 42 days of enrollment consisting of staging laparoscopy, computed tomography (CT) scan of the abdomen and pelvis, and positron emission tomography (PET) scan will be acquired; also endoscopic ultrasound (EUS) tumor and nodal staging will be required
Baseline staging prior to chemoRT initiation must be obtained. If stage IV, there must be documentation by PET/CT scan, CT scan, or MRI, that the patient has evidence of measurable distant disease per RECIST 1.1. Note: Patients with stage IV disease should have limited but measurable metastatic disease (one or two organs involved e.g., liver and lung) and primary tumor deemed resectable.
Ann-Arbor Stage 2 (non-contiguous), 3, or 4 disease per Lugano Classification Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ? 1 lesion that measures ? 1.5 cm in the longest dimension (LD) and ? 1.0 cm in the longest perpendicular dimension (LPD) as assessed by positron emission tomography-computed tomography (PET-CT), computed tomography (CT) or magnetic resonance imaging (MRI)
Imaging of abdomen (CT or CT colonogram or MRI or PET or Ultrasound) within 16 months prior to randomization
Patients must have measurable disease, defined as at least one lesion that is ? 15 mm (? 1.5 cm) in the longest axis on cross-sectional imaging and measurable in two perpendicular dimensions per spiral computed tomography (CT) scan or positron-emission tomography (PET)-CT scan
Positron emission tomography (PET)-positive disease
Patients must have imaging of the chest/abdomen/pelvis, preferably with a computed tomography (CT) scan, and a bone scan within 4 weeks prior to randomization; (NOTE: if a patient is unable to receive CT contrast, a magnetic resonance imaging [MRI] of the abdomen/pelvis and non-contrast chest CT should be performed; positron emission tomography/computed tomography [PET/CT] is not an acceptable alternative)
Subjects must not have evidence of pneumonitis or inflammatory lung disease on CT scan and x-ray
High-quality cross-sectional imaging by computerized tomography (CT) or magnetic resonant imaging (MRI) performed within 6 weeks prior to enrollment and showed a resectable, but high-risk, intrahepatic cholangiocarcinoma (IHCCA) confined to the liver, bile duct, and /or regional lymph nodes. Tumors will be considered high-risk if the high-quality, contrast-enhanced CT and/or MRI +/- positron emission tomography (PET) scan showed:\r\n* T-stage >= Ib (Ib – IV)\r\n* Solitary lesion > 5 cm\r\n* Multifocal tumors or satellite lesions present confined to the same lobe of the liver as the dominant lesion but still technically resectable\r\n* Presence of major vascular invasion but still technically resectable\r\n* Suspicious or involved regional lymph nodes (N1)\r\n* No distant extrahepatic disease (M0)
Measurable disease defined as:\r\n* Computed tomography (CT)/magnetic resonance imaging (MRI)/ or positron emission tomography (PET) scan, with at least one nodal site of disease which is 1.5 cm in longest dimension, and/or spleen > 13 cm in vertical length, and/or diffuse enlargement of liver with or without focal nodules (Lugano 2014); extra nodal sites with biopsy proven abnormal lesions are allowed including skin\r\n* Patients with only bone marrow involvement will be acceptable
At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by computed tomography (CT), positron-emission tomography (PET), magnetic resonance imaging (MRI) and/or bone scan and is suitable for repeated assessment
Presence of metastatic disease on bone or computed tomography (CT) scan \r\n* Evaluable disease progression by modified RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)\r\n* Bone disease on bone scan
No evidence of metastatic disease on baseline imaging (chest x-ray [CXR] or chest CT, abdominal CT or MRI)
Computed tomography (CT) scan and MRI of the pelvis within 120 days prior to enrollment (note: [a] if patient has medical contraindication to MRI, an exemption will be granted and enrollment can proceed [b] for patients with PSA < 1.0 ng/mL, the treatment planning CT can substitute for a diagnostic CT scan)
Bone scan within 120 days prior to enrollment; if the bone scan is suspicious, a plain x?ray and/or MRI must\r\nbe obtained to rule out metastasis, and advanced imaging (e.g., 18NaF positron emission tomography [PET]/CT) is strongly recommended
Must have pathologically-proven adenocarcinoma of the stomach or gastroesophageal (GE)-junction, stage M0, as established by both imaging and surgical pathologic staging.\r\n* Imaging: Clinical stage of M0 will be established by either computed tomography (CT) (chest with contrast and abdomen/pelvis with and without contrast), or CT/positron emission tomography (PET) (skull base to mid-thigh). This is standard post-surgery imaging.\r\n*Surgery: Surgical pathologic staging must be M0.
Staging computed tomography (CT) scans done prior to enrollment
Patients must have a FDG-PET-computed tomography (CT) of chest, abdomen, and pelvis within 28 days of enrollment
Pre-operative scans including MRI/computed tomography (CT) neck and, CT chest with contrast; if contrast is contraindicated, staging positron emission tomography (PET) or PET-CT is acceptable although high quality/diagnostic cross-sectional imaging of the head and neck area is recommended
Radiologic workup must demonstrate that the disease is confined to the abdominal cavity and/or is not metabolically active on PET (positron emission tomography scan), outside of the abdominal cavity
Clinical evidence of local recurrence or distant metastases; Note: all patients must have either a positron emission tomography (PET)/computed tomography (CT) or a CT of chest, abdomen and pelvis and a bone scan; if one or more of these is concerning for distant metastases, follow-up imaging and/or biopsy should be performed to rule out distant metastases prior to randomization
Diagnostic quality, cross sectional imaging of the thorax within 28 days prior to registration; 18-F-FDG-PET/CT or conventional CT are acceptable.
Diagnostic quality CT or MRI of neck, with contrast, within 28 days prior to registration; a 18-F-FDG-PET/CT of the neck only is acceptable as a substitute if the CT is of diagnostic quality and with IV contrast.
The tumor must be clinically determined to be locally advanced stage II or stage III rectal cancer, and must also meet any ONE of the following criteria:\r\n* Distal location (as defined by measurement on magnetic resonance imaging [MRI], transrectal ultrasound [ERUS]/pelvic computed tomography [CT] [with IV contrast] scan or palpable on digital rectal examination [DRE]): cT3-4 =< 5 cm from the anal verge, any N\r\n* Bulky: any cT4 or evidence that the tumor is adjacent to (defined as within 3 mm of) the mesorectal fascia on MRI or ERUS/pelvic CT (with IV contrast) scan\r\n* High risk for metastatic disease with 4 or more regional lymph nodes (cN2); clinical nodal or \cN\ status for eligibility includes the total number of nodes (N2 = 4 or more) in the mesorectal and superior rectal stations measuring >= 1.0 cm in any axis on cross sectional or endoscopic imaging; Note: nodes must measure 1.0 cm or greater to be considered positive for this eligibility requirement\r\n* Not a candidate for sphincter-sparing surgical resection prior to neoadjuvant therapy (as planned by the primary surgeon)\r\n** Note: clinical stage of the primary tumor and nodes may be determined locally by rectal endoscopic ultrasound or pelvic MRI (MRI is strongly preferred); CT scan with IV contrast is acceptable provided there is evidence of T4 and/or N2 disease
Definitive clinical or radiologic evidence of metastatic disease; required imaging studies must have been performed within 28 days prior to randomization; Note: Distant clinical staging to exclude patients with overt metastatic disease is determined by:\r\n* Chest: CT scan (preferred); chest x-ray posterioranterior (PA) and lateral (acceptable); or positron emission tomography (PET) scan (acceptable)\r\n* Abdomen: CT scan with IV contrast (preferred); or MRI (acceptable)\r\n* Pelvis: MRI (preferred) or CT scan with IV contrast (acceptable)\r\n** (It is recommended that the same imaging tests that are performed before randomization be used at follow-up time points; Note: CT scans of the abdomen and pelvis must be performed with IV contrast)
Pathologic stage III or IV HNSCC, including no distant metastases, based on the following minimum diagnostic workup:\r\n* General history/physical examination by a radiation oncologist and/or medical oncologist within 84 days prior to registration\r\n* Examination by an ear nose and throat (ENT) or head & neck surgeon prior to surgery; a laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure), if appropriate, is recommended but not required; intra-operative examination is acceptable documentation\r\n* Pre-op Imaging of the head and neck: a neck computerized tomography (CT) (with contrast) or CT/positron emission tomography (PET) (with contrast) and/or an magnetic resonance imaging (MRI) of the neck (T1 with gadolinium and T2) within 84 days prior to surgery; note: this imaging data (diagnostic pre-operative scan showing gross disease) is to be submitted in Digital Imaging and Communications in Medicine (DICOM) format via transfer of images and data (TRIAD); the report is to be uploaded into Rave\r\n* Chest imaging with either a CT scan (with or without contrast) or CT/PET (with or without contrast) that includes the chest within 120 days prior to registration; Note: if the CT/PET with or without contrast is done within 84 days prior to surgery, it fulfills the chest imaging requirement
Pathologic stage III or IV HNSCC, including no distant metastases, based upon the following minimum diagnostic workup:\r\n* General history and physical examination by a radiation oncologist and/or medical oncologist within 84 days prior to registration;\r\n* Examination by an ear nose throat (ENT) or head & neck surgeon prior to surgery; a laryngopharyngoscopy (mirror and/or fiber optic and/or direct procedure), if appropriate, is recommended but not required; intra-operative examination is acceptable documentation\r\n* Pre-operative (op) Imaging of the head and neck: A neck computed tomography (CT) (with contrast) or CT/positron emission tomography (PET) (with contrast) and/or an magnetic resonance imaging (MRI) of the neck (T1 with gadolinium and T2) within 84 days prior to surgery; Note: this imaging data (diagnostic pre-operative scan showing gross disease) is to be submitted in Digital Imaging and Communications in Medicine (DICOM) format via TRIAD; the report is to be uploaded into Rave\r\n* Chest CT scan (with or without contrast) or CT/PET that includes the chest (with or without contrast) either within 84 days prior to surgery or within 120 days prior to registration; Note: if the CT/PET with or without contrast is done within 84 days prior to surgery, it fulfills the chest imaging requirement
CT imaging review submission to confirm unilateral pleural involvement; this review for CT imaging is mandatory prior to registration to confirm eligibility; it should be initiated as soon as possible after pre-registration
Patient must be able to tolerate imaging requirements of an 18-FDG-PET-CT scan
Patients with hypermetabolic para-aortic disease identified on baseline 18-FDG-PET-CT
Melanoma cohort only: measurable disease defined as at least one lesion whose longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with computed tomography (CT) scan or magnetic resonance imaging (MRI) scan; or CT component of a positron emission tomography (PET)/CT; NOTE: disease that is measurable by physical examination only is not eligible
Gynecologic cancer cohort only: measureable disease, defined as at least one lesion whose longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with CT scan or MRI scan; or CT component of a PET/CT; NOTE: Disease that is measurable by physical examination only is not eligible; EXCEPTION: Patients with ovarian, fallopian, or peritoneal cancer without measurable disease are eligible if two pretreatment CA125 values (documented on two occasions taken at least one week apart) are at least twice the upper limit of normal or twice the nadir value if pretreatment CA125 values never normalized.
The patient must be free of unresectable metastatic disease within 4 weeks prior to the surgery being performed with the intention to remove all melanoma; this pre-surgery baseline assessment must be documented by complete physical examination and imaging studies; imaging studies must include a total body positron emission tomography (PET)-computed tomography (CT) in conjunction with a brain magnetic resonance imaging (MRI) (or head CT if brain MRI is contraindicated); if a PET/CT scan cannot be done, a CT of the neck, chest, abdomen, and pelvis should be performed
Must have American Joint Committee on Cancer (AJCC) 7th edition (ed) inoperable stage II disease requiring chemoradiation therapy or stage IIIA or IIIB NSCLC based on appropriate staging studies including brain magnetic resonance imaging (MRI) or head computed tomography (CT), CT chest, and fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT scan
All patients must have disease-free status documented by a complete physical examination and imaging studies within 4 weeks prior to randomization; imaging studies must include a total body positron emission tomography (PET)-computed tomography (CT) scan (with or without brain) and brain magnetic resonance imaging (MRI) or CT (if MRI is contraindicated); if PET-CT cannot be done, CT of neck, chest, abdomen, and pelvis should be done\r\n* If for some reason a CT cannot be done, an MRI may be done instead; any other imaging studies if performed (eg, bone scan) must show no evidence of disease
Measurable disease, defined as one or more of the following:\r\n* Lymphocytosis >= 5000 in peripheral blood\r\n* Measurable lymph nodes > 1.5 cm on palpation and/or computed tomography (CT) scan\r\n* Organomegaly by physical exam and/or CT scan
If remission status < 1 year for NHL, complete remission documented by computed tomography (CT) or positron emission tomography (PET)-CT scan within 3 months of study entry
Patients must have radiographically measurable disease (with the exception of those with neuroblastoma)\r\n* Measurable disease is defined as the presence of at least one lesion on magnetic resonance imaging (MRI) or computed tomography (CT) scan that can be accurately measured with the longest diameter a minimum of 10 mm in at least one dimension (CT scan slice thickness no greater than 5 mm)\r\n* Note: the following do not qualify as measurable disease: \r\n** Malignant fluid collections (e.g., ascites, pleural effusions)\r\n** Bone marrow infiltration except that detected by metaiodobenzylguanidine (MIBG) scan for neuroblastoma\r\n** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted in patients with neuroblastoma who do not have measurable disease but have MIBG-avid evaluable disease \r\n** Elevated tumor markers in plasma or cerebrospinal fluid (CSF) \r\n** Previously radiated lesions that have not demonstrated clear progression post radiation \r\n** Leptomeningeal lesions that do not meet the measurements noted above
New or progressive pulmonary infiltrates on screening chest x-ray or chest computed tomography (CT) scan that has not been evaluated with bronchoscopy; infiltrates attributed to infection must be stable/improving (with associated clinical improvement) after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections); surgical resection waives any waiting requirements
Negative metastatic workup with bone scan and computed tomography (CT) abdomen/pelvis, within 6 months of study treatment, if indicated by PSA > 10
Patients must demonstrate >= 75% disease reduction on computed tomography (CT) scan (confirmed by positron emission tomography [PET] scan) after the third cycle of R-EPOCH relative to baseline, with no evidence of disease progression after the fifth cycle
Computed tomography (CT) chest, abdomen, and pelvis performed
Clinical stage T1-T2, N1-N2b or T3, N0-N2b (American Joint Committee on Cancer [AJCC], 7th edition [ed.]) including no distant metastases based on the following diagnostic workup:\r\n* General history and physical examination within 56 days prior to registration\r\n* Fiberoptic exam with laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure) within 70 days prior to registration\r\n* One of the following combinations of imaging is required within 56 days prior to registration:\r\n** A CT scan of the neck (with contrast) and a chest CT scan (with or without contrast)\r\n** Or a magnetic resonance imaging (MRI) of the neck (with contrast) and a chest CT scan (with or without contrast)\r\n** Or a CT scan of neck (with contrast) and a PET/CT of neck and chest (with or without contrast)\r\n** Or an MRI of the neck (with contrast) and a PET/CT of neck and chest (with or without contrast)\r\n*** Note: a CT scan of neck and/or a PET/CT performed for the purpose of radiation planning may serve as both staging and planning tools
Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:\r\n* History/physical examination, including documentation of height, weight, body surface area [BSA], and vital signs, within 30 days prior to registration\r\n* Computed tomography (CT) with IV contrast or magnetic resonance imaging (MRI) imaging (if CT scan with contrast is medically contraindicated) of the lung and upper abdomen through the adrenal glands, required within 45 days prior to registration (recommended within 30 days prior to registration\r\n* MRI of the brain with contrast (or CT with contrast if MRI is medically contraindicated) within 45 days prior to registration; note: the use of intravenous contrast is required for the MRI or CT; an MRI without contrast is only permitted if the patient has a contrast allergy\r\n* Whole-body fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/CT required within 45 days prior to registration (recommended within 30 days prior to registration; note: patients do not need to have a separate CT of the chest and upper abdomen with contrast if PET/CT imaging includes a high quality CT with contrast
Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the study if liver imaging (computed tomography [CT], MRI, positron emission tomography [PET]-CT, or PET scan) performed within 6 weeks prior to randomization does not demonstrate metastatic disease and the requirements are met
Patients with alkaline phosphatase that is > ULN but =< 2.5 x ULN or unexplained bone pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan performed within 6 weeks prior to randomization does not demonstrate metastatic disease
No distant metastases, based upon the following minimum diagnostic workup:\r\n* History/physical examination within 30 days prior to registration\r\n* Whole body fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/CT within 30 days prior to registration\r\n** NOTE: if whole-body FDG-PET/CT is not performed, CT of the chest and CT (or MRI) of abdomen and pelvis must be obtained (imaging of abdomen and pelvis need not be repeated if already included in pancreas protocol study)
New progressive pulmonary infiltrates on screening chest x-ray or chest computed tomography (CT) scan for which evaluation with bronchoscopy is not feasible; infiltrates attributed to infection must be stable/improving (with associated clinical improvement) after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections)
Disease evaluable by computed tomography (CT) or positron emission tomography (PET) imaging
No history of cardiomegaly or bilateral pulmonary infiltrates on chest radiograph or computed tomography (CT); however, patients with cardiomegaly on imaging may be enrolled if they have an assessment of cardiac function (i.e., echocardiography [ECHO] or multi gated acquisition scan [MUGA]) within 3 weeks of starting protocol therapy that is within normal limits; additionally, patients with bilateral pulmonary infiltrates on imaging may be enrolled if the lesions are not consistent with active neuroblastoma (i.e., negative on functional imaging with PET or MIBG, or by pathologic assessment)
Pretreatment positron emission tomography (PET) computed tomography (CT) scan to rule out metastatic disease \r\n* The primary tumor may not be larger than 8 cm in maximum dimension; mediastinal and hilar lymphadenopathy can be no larger than 5 cm at any nodal station; if the primary tumor is central in location, defined as within 2 cm from the tracheobronchial tree, it must be no larger than 5 cm
Patients are preferred to have either a tumor mass amenable to core needle biopsy during the dosimetry phase, or a measurable tumor mass with at least one site of involvement measuring 2.5 cm in largest dimension on computed tomography (CT) imaging for purposes of planar and/or single-photon emission computed tomography (SPECT)/CT tumor dosimetry
Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:\r\n* History/physical examination within 45 days prior to registration\r\n* Computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)-CT including the abdomen and pelvis should be performed for initial radiological staging; this may be performed pre- or post-surgery within 90 days prior to registration; imaging performed post-operatively should show no evidence of residual disease; any evidence of malignancy identified on pre-operative imaging should have been completely resected surgically prior to protocol treatment; chest CT or chest x-ray must be performed within 90 days prior to registration (unless a PET-CT has been performed)
Patients must undergo pre-treatment endoscopic tumor staging and positron emission tomography (PET)-computed tomography (CT) scanning
Appropriate diagnostic imaging performed including a CT or MRI of the brain and CTs of the thorax, abdomen, pelvis; CT of the neck and imaging of the extremities may be indicated depending on the clinical presentation must be complete and satisfactory within 30 days of initiation of chemotherapy
Histologically documented adenocarcinoma of the prostate with metastatic disease as evidenced by soft tissue (e.g. lymphoid) and/or bony metastases on baseline computed tomography (CT) scan of the abdomen and pelvis and/or bone scan
FDG-PET/CT scan for staging and RT plan within 4 weeks prior to registration
CT scan or sim CT of chest and upper abdomen (IV contrast is recommended unless medically contraindicated) within 6 weeks prior to registration
Able to tolerate PET/CT imaging required to be performed at an American College of Radiology (ACR) Imaging Core Laboratory (Lab) qualified facility
No evidence of systemic non-Hodgkin lymphoma as demonstrated by a computed tomography (CT) scan of the chest, abdomen, and pelvis within 6 weeks prior to registration (note: bone marrow biopsy is not required for registration but must be obtained prior to start of treatment)
Patients will have a baseline computed tomography (CT) chest, abdomen and pelvis within 30 days of registration
The following minimum diagnostic workup is required:\r\n* History/physical examination within 2 weeks prior to registration\r\n* Imaging of neck and brain (computed tomography [CT] scan or magnetic resonance imaging [MRI]) and chest/abdominal imaging (chest x-ray or chest CT scan, or full body positron emission tomography [PET]/CT are acceptable) within 4 weeks prior to registration\r\n* Note: the CT scan of the neck must be done with contrast or if an MRI is done, with gadolinium; therefore, the CT portion of a full body PET/CT has to be a high resolution CT to be acceptable for eligibility\r\n* Abdominal imaging must cover the liver and adrenal glands; therefore, separate imaging is not required if these areas are covered by a chest CT scan\r\n* Electrocardiogram within 10 days prior to registration
Stage T1N1-2, T2-3N0-2, according to the American Joint Committee on Cancer (AJCC) 7th edition staging, based on the following minimum diagnostic work-up:\r\n* Chest/abdominal/pelvic computed tomography (CT) or whole-body positron emission tomography (PET)/CT (NOTE: if CT is performed at this time point, whole-body PET/CT will be required prior to step 2 registration; PET/CT of skull base to mid-thigh is acceptable) (NOTE: if adenopathy is noted on CT or whole-body PET/CT scan, an endoscopic ultrasound is not required prior to STEP 2 registration as long as adequate tissue has been obtained for central HER2 testing)\r\n* Patients may have regional adenopathy including para-esophageal, gastric, gastrohepatic and celiac nodes; if celiac adenopathy is present, it must be =< 2 cm\r\n* Patients with tumors at the level of the carina or above must undergo bronchoscopy to exclude fistula
Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:\r\n* History/physical examination, including a neurological assessment, within 8 weeks of registration\r\n* Evaluation by a thoracic surgeon within 4 weeks of registration; the patient must be deemed potentially operable and resectable to be eligible for the study\r\n* Whole body fludeoxyglucose F 18 (FDG)-PET (or PET/CT) scan within 6 weeks of registration\r\n* A magnetic resonance imaging (MRI) with contrast of the brain (or CT scan with contrast of brain, if an MRI is medically contraindicated) within 5 weeks of registration\r\n* A CT scan with contrast of the lungs and upper abdomen to complete T and N staging and exclude other ipsilateral or contralateral parenchymal lesions and liver or adrenal metastases within 5 weeks of registration
All responses are to be determined using the response criteria for non-hodgkin’s lymphoma and will include PET/computed tomography (CT) prior to hematopoietic cell transplantation (HCT)
Patients may have measurable or non-measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI) within 42 days prior to registration; the CT from a combined positron emission tomography (PET)/CT may be used only if it is of diagnostic quality; laboratory parameters are not acceptable as the only evidence of disease; in order to qualify as measurable, measurable disease must be outside previous radiation field; all disease must be assessed and documented on the Baseline Tumor Assessment Form (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
Fluorodeoxyglucose (FDG)-avid disease by positive emission tomography (PET), and measurable disease greater than 1.5 cm in diameter
A complete response to front-line chemotherapy must include: negative physical exam, negative pelvic exam and normalization of CA125, if elevated at baseline; although not required, any radiographic assessment of disease status (e.g. CT, magnetic resonance imaging [MRI], positron emission tomography [PET]/CT, etc) obtained following the completion of primary therapy should be considered negative for disease
One or more tumors measurable on CT scan/MRI scan per RECIST v 1.1. - Previously irradiated tumors may be eligible if they have clearly progressed in size.
Patients must have staging scans with abdominal/pelvic computed tomography (CT) or magnetic resonance imaging (MRI) scan and CT scan or x-ray of the chest within 56 days prior to registration; if alkaline phosphatase is above the treating institution’s upper limit of normal (ULN), presence of suspicious bone pain, or if other clinical suspicion, a whole body bone scan is required within 56 days prior to registration
Patients must have a diagnostic quality contrast-enhanced CT scan of the chest, abdomen, and pelvis AND baseline FDG-PET scan performed within 28 days prior to registration\r\n* Low-resolution \localization\ CT scans performed as part of a combined PET/CT scan are not adequate for enrollment or response determination on this protocol\r\n* If a patient has an allergy to CT contrast, then a non-enhanced CT will be acceptable
Interim PET/CT scans must have been submitted for centralized review
Para-aortic nodal involvement above the level of the common iliac nodes or L3/L4 (if biopsy proven, PET positive, or >= 15 mm short-axis diameter on computed tomography [CT])
All patients must have disease-free status documented by a complete physical examination and imaging studies within 42 days prior to registration; imaging studies must include a total body positron emission tomography (PET)-computed tomography (CT) scan that is of diagnostic quality (with or without brain) or a CT of the chest, abdomen and pelvis; for patients with melanoma arising from the head and neck, dedicated neck imaging (CT with IV contrast or PET-CT through the region) is required; if the patient has had unknown primary with disease in the axilla, neck imaging is required to assure region is clear of cancer; CT imaging should be done with intravenous contrast if there are no contraindications for it; any other clinically-indicated imaging studies if performed (e.g. bone scan) must show no evidence of disease
Patient must have no evidence of disease on post-operative imaging:\r\n* A computed tomography (CT) of the chest must be obtained within 4 weeks prior to randomization with or without contrast\r\n* A CT of the abdomen/pelvis must be obtained within 4 weeks prior to randomization with intravenous (IV) contrast (oral contrast may be added at the radiologist’s discretion); an magnetic resonance imaging (MRI) of the abdomen/pelvis with gadolinium may be substituted for the CT if the CT with IV contrast is contra-indicated\r\n* An MRI of the brain with and without gadolinium must be done within 8 weeks prior to randomization; a CT of the brain with and without IV contrast is permitted if MRI is contra-indicated (i.e., pacemaker)
DISEASE RELATED CRITERIA: Patients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI) within 28 days prior to registration; the CT from a combined positron emission tomography (PET)/CT may be used only if it is of diagnostic quality; non-measurable disease must be assessed within 42 days prior to registration; all known sites of disease must be assessed and documented on the baseline tumor assessment form (Response Evaluation Criteria in Solid Tumors [RECIST 1.1])
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, defined as at least one lesion that can be accurately measured in at least one dimension >= 10 mm (>= 1 cm) by computed tomography (CT) imaging or magnetic resonance imaging (MRI) within 42 days prior to registration; the CT from a combined positron emission tomography (PET)/CT may be used only if it is of diagnostic; laboratory parameters are not acceptable as the only evidence of disease
Bone scan or positron emission tomography (PET) scan; required only if alkaline phosphatase (ALP) is ?2 x upper limit of normal (ULN) and/or there are symptoms of metastatic bone disease. A confirmatory imaging study is required if the results from the bone scan are questionable
Phase I (Cohorts T, and T2): Greater than or equal to (>/=) 1 bi-dimensionally measurable lesion on computed tomography (CT) scan
Patients must not have any evidence of residual or metastatic renal cell cancer on computed tomography (CT) scan of the chest, abdomen, and pelvis, all with oral and intravenous (IV) contrast after nephrectomy and within a maximum of 28 days prior to registration; a magnetic resonance imaging (MRI) scan of the abdomen/pelvis with gadolinium and a non-contrast CT of the chest is an acceptable imaging alternative; non-contrast CT of the chest/abdomen/pelvis should only be performed if, in the opinion of the investigator, it is in the best medical interest of the patient to not receive IV contrast of any form; NOTE: positron emission tomography (PET)/CT is not an acceptable imaging alternative; patients who display subcentimeter pulmonary nodules (by CT scan) that are non-specific and considered unlikely to represent metastatic disease by the treating investigator will be considered eligible
(B) Bone lesions (lytic or osteopenic) one or more bone lesions on skeletal radiography, Computed tomography (CT), or PET-CT
Steroids as premedication for hypersensitivity reactions (eg, computed tomography (CT) scan premedication);
Patients must have resectable primary tumor based on contrast-enhanced CT or MRI (CT or MRI without contrast as part of positron emission tomography [PET]/CT or PET/MRI is NOT acceptable; CT or MRI with contrast as part of PET/CT or PET/MRI is acceptable) of the chest, abdomen, and pelvis; the local interpreting radiologist must review the scans and sign the S1505 local radiology checklist prior to registration; resectable is defined as:\r\n* No involvement of the celiac artery, common hepatic artery, and superior mesenteric artery (and, if present, replaced right hepatic artery)\r\n* No involvement, or < 180 degrees interface between tumor and vessel wall, of the portal vein and/or superior mesenteric vein; and patent portal vein/splenic vein confluence\r\n* No evidence of metastatic disease; lymphadenopathy (defined as nodes measuring > 1 cm in short axis) outside the surgical basin (i.e., para-aortic, peri-caval, celiac axis, or distant nodes) is considered M1 disease and makes the patient ineligible; if, however, such nodes are biopsied and are negative, then enrollment can be considered after review with the study chairs\r\n* Note: for tumors of the body and tail of the pancreas, involvement of the splenic artery and vein of any degree is considered resectable disease
Abdominal/pelvic computed tomography (CT) scan with contrast is preferred; abdominal CT alone is acceptable only if insurance restrictions are experienced; chest CT/x-ray (CT of chest preferred) within 31 days of registration on study (or within 31 days prior to day 1 of chemo post-surgery for those patients having started chemotherapy prior to first step registration); patients allergic to intravenous (IV) contrast can have magnetic resonance imaging (MRI) of the abdomen/pelvis instead
Clinical stage T1, N1-2 or T2-4a, N0-2, M0 including no distant metastases, based upon the following minimum diagnostic workup:\r\n* General history and physical examination by a radiation oncologist and/or medical oncologist within 8 weeks prior to registration\r\n* Examination by an ear, nose and throat (ENT) or head & neck surgeon, within 8 weeks prior to registration; a laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure) is recommended but not required\r\n* Chest x-ray (at a minimum) or chest computed tomography (CT) scan (with or without contrast) or CT/positron emission tomography (PET) of chest (with or without contrast) within 8 weeks prior to registration
Measurable nodal disease by computed tomography (CT)
Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)
Patients must have measurable disease (at least 1 lesion of >= 1.5 cm in one diameter) as detected by computed tomography (CT) or the CT images of the positron emission tomography (PET)/CT
CT scan with IV contrast (CT scan without contrast acceptable if IV contrast is medically contraindicated) of the lung and upper abdomen through the adrenal glands within 60 days prior to registration (recommended within 30 days prior to registration)
Whole-body FDG-PET/CT within 60 days prior to registration; Note: patients do not need to have a separate CT of chest and upper abdomen with contrast if PET/CT imaging includes a high quality CT chest with contrast.
Imaging (positron emission tomography/computed tomography (PET/CT) scan, CT scan, or magnetic resonance imaging (MRI)) of chest, abdomen, and pelvis must be performed within 90 days prior to randomization and must demonstrate no evidence of metastatic disease. If findings noted in imaging study reports are equivocal, the determination of whether or not the findings represent metastatic disease will be at the investigator's discretion.
Patients must have metastatic disease. Baseline imaging of chest, abdomen and pelvis (CT or MRI) within 21 days prior to initiation of protocol therapy is required.
Patients must have at least one measurable lesion that can be followed for response assessment on baseline imaging obtained no more than 28 days prior to beginning study therapy. Baseline and follow up radiological disease assessment must include bone scans performed with either Technetium-99m labeled diphosphonates or Fluorine-18 sodium fluoride PET or PET/CT, as per the local standard of care for patients with prostate cancer.
Bidimensional measurable disease of at least 1.5 cm in the greatest transverse diameter as documented by computed tomography (CT) or positron emission tomography (PET)/CT
Participants must have histologically or cytologically confirmed invasive squamous, basaloid, or cloacogenic carcinoma of the anal canal; pathology must be reviewed by the treating institution; patients must be clinically staged as T stage 1-4 and N0-N3 stage, based upon the following minimum diagnostic work-up:\r\n* History/physical examination within 42 days prior to registration\r\n* Anal examination with mandatory biopsy and any of the following: colonoscopy, sigmoidoscopy, rigid proctoscopy, or anoscopy; digital rectal examination (performed at the discretion of the treating physician) with documentation of primary anal lesion size, distance from the anal verge, and anal tone is also recommended\r\n* Groin examination with documentation of any groin adenopathy and lymphadenopathy (location: right vs. left, medial vs. lateral, mobile vs. fixed, and size)\r\n* A biopsy is not needed for pathologically enlarged or clinically suspicious inguinal, perirectal, or pelvic lymph nodes on examination, computed tomography (CT) scan, or positron emission tomography (PET)/CT and will be considered clinically positive\r\n* No evidence of distant metastatic disease as determined by CT scan with contrast, or PET/CT scan of the chest within 42 days prior to registration and CT scan with contrast, magnetic resonance imaging (MRI), or PET/CT of the abdomen and pelvis within 42 days prior to registration
Pretreatment evaluations required for eligibility include:\r\n* A medical history, physical examination, assessment of Zubrod performance status within 4 weeks prior to study entry;\r\n* Complete blood count (CBC) with differential and platelet count, and laboratory profile must be completed within 4 weeks prior to study entry;\r\n* FEV1, CT scan or magnetic resonance imaging (MRI) of the chest, a bone scan (or positron emission tomography [PET] or PET/CT), and a CT scan or MRI of the brain (to rule out brain metastasis) within 6 weeks prior to study entry;\r\n* Medical Oncology and Radiation Oncology consults and approval
Patients must have a chest CT scan, or PET/CT scan to rule out metastatic disease
Patients must have a contrast enhanced CT scan or MRI or PET/CT scan of the tumor site and neck nodes prior to entering the study.
Patients must be in complete remission at D60-180 after AHCT as evidenced by computed tomography (CT) scan of the neck/chest/abdomen (abd)/pelvis or CT/positron emission tomography (PET) scans
No evidence of bone metastases (M0) on bone scan (Na F positron emission tomography (PET)/CT is an acceptable substitute) within 120 days prior to step 1 registration\r\n* Equivocal bone scan findings are allowed if plain films and/or MRI are negative for metastasis
Bi-dimensionally measurable disease, with at least one mass lesion >= 2 cm in longest diameter\r\nby computed tomography (CT), positron emission tomography (PET)/CT, and/or magnetic resonance imaging (MRI)
pathologically confirmed mantle cell lymphoma (MCL), with (a) measurable nodal disease on positron emission tomography computed tomography (PET-CT) per Lugano classification. Prior to enrollment, pathology must be reviewed and confirmed at the investigational site where the participant is entered
Either FDG-avid on FDG-PET or measurable disease by CT on cross sectional imaging: > 1.5 cm for nodal lesion, > 1.0 cm for extra nodal lesion.
CT scan that demonstrates no evidence of disease (NED) after completion of adjuvant therapy Note: This CT scan will also be used for Texture analysis.
A PET/computed tomography (CT) scan is required; patients with hilar or mediastinal lymph nodes with short axis diameter =< 1 cm and no abnormal hilar or mediastinal uptake on PET will be considered N0; patients with > 1 cm short axis diameter of hilar or mediastinal lymph nodes on CT or abnormal PET (including suspicious but non-diagnostic uptake) may still be eligible if directed tissue biopsy of all abnormally identified areas are negative for cancer; solitary pulmonary lesions =< 6 mm will not be considered significant
PET/CT scan to include both lungs, the mediastinum, and adrenal glands; primary tumor dimension will be measured on diagnostic CT and again on simulation CT; must be done within 10 weeks prior to study entry
Progression of bi-dimensionally measurable soft tissue (nodal metastasis) assessed within 1 month prior to registration by a CT scan or MRI of the abdomen and pelvis.
Patients with history of second malignancy are eligible if they have documentation of disease stability, off therapy, based on computed tomography (CT) scan or other measures for the 6 months prior to entry in core
Subjects with HL with no available curative treatment options (such as autologous stem cell transplant [SCT]) who have a limited prognosis (several months to < 2 year survival) with currently available therapies will be enrolled\r\n* HL with biopsy-proven relapse or refractory disease who are unresponsive to or intolerant of at least one line of standard salvage therapy\r\n* Patients must have evaluable disease by radiologic imaging (fluorodeoxyglucose [FDG] positron emission tomography [PET]/computed tomography [CT] or PET/magnetic resonance imaging [MRI]) within 42 days of enrollment; evaluable includes both assessable and/or measurable disease as defined by Cheson et al., 2007
The following imaging workup to document metastases within 45 days prior to study registration: \r\n* Computed tomography (CT) scans of the chest, abdomen and pelvis with radionuclide bone scan OR whole body positron emission tomography (PET)/CT
Patients with radiographic evidence of metastatic prostate cancer (stage M1 or D2). Distant metastases evaluable by radionuclide bone scan, CT scan, or MRI within 28 days before the start of study treatment.
Patients must have measurable or non-measurable metastatic disease; computed tomography (CT) scans or magnetic resonance imagings (MRIs) used to assess all disease must have been completed within 28 days prior to Step 2 Randomization; CT scans or MRIs must be assessed and documented on the Baseline Tumor Assessment Form (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
Metastatic lesions identifiable only by positron emission tomography (PET)
Evidence of diverticulitis at baseline, including evidence limited to computed tomography (CT) scan only
Bone marrow involvement based on CT or PET scan at screening
Patients must have histologically or cytologically diagnosed pancreatic adenocarcinoma; documentation of disease extent by computed tomography (CT) scan is required; radiologically measurable disease is not required
Patients must have a magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET) of the brain within 2 months before consenting if known history of brain metastasis or if clinically indicated; if new lesions are present, principal investigator (PI) or designee should make final determination regarding enrollment
Patients must have brain imaging by MRI, CT or PET within 30 days prior to lymphodepletion; patients may have asymptomatic brain lesions that are =< 1 cm each, lesions that are > 1 cm that have been irradiated and in the opinion of the investigator no longer represents active disease will also be allowed
Patients must have at least ONE of the following:\r\n* Measurable tumor on magnetic resonance imaging (MRI), computed tomography (CT) scan obtained within 3 weeks prior to study entry; measurable is defined as >= 10 mm in at least one dimension on spiral/helical CT that is metaiodobenzylguanidine (MIBG) avid or demonstrates increased fludeoxyglucose (FDG) uptake on positron emission tomography (PET) scan\r\n* MIBG scan obtained within 3 weeks prior to study entry with positive uptake at a minimum of one site; this site must represent disease recurrence after completion of therapy, progressive disease on therapy, or refractory disease during induction\r\n* Patients with resistant/refractory soft tissue disease that is not MIBG avid or does not demonstrate increased FDG uptake on PET scan must undergo biopsy to document the presence of viable neuroblastoma; biopsy is not required for patients who have new site of soft tissue disease (radiographic evidence of disease progression) regardless of whether progression occurs while receiving therapy or after completion of therapy\r\n* Note: Patients with elevated catecholamines (i.e., > 2 x ULN) only or bone marrow disease only are NOT eligible for this study
To rule out metastatic disease, patients must have the following tests:\r\n* Bone scan within 60 days prior to registration\r\n* Computed tomography (CT) of abdomen/pelvis within 60 days prior to registration
Subjects must have measurable or evaluable disease based on physical exam and/or radiographs (computed tomography [CT], magnetic resonance imaging [MRI], positron emission tomography [PET]) or bone marrow involvement
Evidence of metastatic disease in bone on bone scan, CT scan, and/or by MRI at any time following the initial diagnosis of prostate cancer
Patients must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive metaiodobenzylguanidine [MIBG] or positron emission tomography [PET] scans) or measurable (computed tomography [CT], magnetic resonance imaging [MRI]) disease documented after completion of prior systemic therapy
Negative radiographic metastatic work-up including whole body radionuclide bone scan, computed tomography (CT), and/or magnetic resonance (MR) scan of the pelvis and abdomen, and chest x-ray; patients with suspicious areas on conventional imaging studies may be included if they are biopsy negative
Contrast enhanced CT of the chest and upper abdomen
PET/CT
Participants must have had PET-computed tomography (CT) for restaging after salvage therapy and before ASCT
Evidence of metastatic disease as determined by chest computed tomography (CT) scan, abdomen/pelvis CT scan (or magnetic resonance imaging [MRI] with gadolinium and/or manganese) within six weeks of study entry; distant nodal disease is allowed if it is in the radiation port
Subject has evidence of pre-existing idiopathic pulmonary fibrosis on computed tomography (CT) scan at baseline
Presence of evaluable disease by positron emission tomography (PET) imaging per the Lugano classification
DCFPyL-PET/MRI or DCFPyL-PET/CT scan within the past 6 months with results that demonstrate more disease lesions than baseline CT/bone scan
Unable to lie flat during or tolerate PET/MRI, PET/CT or SBRT
Histologically confirmed adenocarcinoma of the prostate with progressive metastatic disease which, in the opinion of the investigator, requires initiation of new treatment. The assessment of disease progression can be based on either PSA rise, new or progressive soft tissue disease (based on computed tomography [CT] or magnetic resonance imaging [MRI] scans), or new or progressive bony disease based on radionuclide bone scan or 18F-sodium fluoride positron emission tomography/computed tomography [NaF PET/CT] scans). Participants being considered for Cohort 2B must, in addition, have primary or metastatic lesions amenable to tumor biopsies
Evidence of myeloma defining events or biomarkers of malignancy due to underlying plasma cell proliferative disorder meeting at least one of the following\r\n* 1) Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the upper limit of normal or > 2.75 mmol/L (> 11 mg/dL)\r\n* 2) Renal insufficiency: creatinine clearance < 40 ml/min or serum creatinine > 2 mg/dL\r\n* 3) Anemia: hemoglobin value < 10 g/dL or 2 g/dL < normal reference\r\n* 4) Bone lesions: one or more osteolytic lesions on skeletal radiography, computerized tomography (CT) or 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography CT (PET-CT)\r\n* 5) Clonal bone marrow plasma cell percentage >= 60%\r\n* 6) Involved: uninvolved serum free light chain ratio >= 100 measured by Freelite assay (The Binding Site Group, Birmingham, United Kingdom [UK])\r\n* 7) > 1 focal lesions on magnetic resonance imaging (MRI) studies (each focal lesion must be 5 mm or more in size), if clinically indicated
Patients with measurable disease; patients with non-measurable but evaluable disease may be eligible after discussion with the principal investigator (PI); baseline measurements and evaluations must be obtained within 6 weeks of registration to the study; abnormal positron emission tomography (PET)/computed tomography (CT) scans will not constitute evaluable disease, unless verified by CT scan or other appropriate imaging
Bi-dimensionally measurable disease, with at least one mass lesion >= 2 cm in longest diameter by computed tomography (CT), positron emission tomography (PET)/CT, and/or magnetic resonance imaging (MRI)
Complete remission (CR) according to the Revised Response Criteria for Malignant Lymphoma after first-line treatment\r\n* Diagnostic CT scans with contrast of chest, abdomen, and pelvis must have been performed within 8 weeks from the first day of the last cycle of R-chemotherapy; a neck CT will be required if the patient had involvement of the neck region at initial diagnosis\r\n* A negative fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/CT scan performed within 8 weeks from the first day of the last cycle of R-chemotherapy and confirming CR, with negative defined as a score of 1-3 on the Deauville 5-point scale used to quantify radionucleotide density in PET scans as determined locally; PET positive/indeterminate lesions which are confirmed on biopsy to harbor no active lymphoma will be considered negative for determination of CR status\r\n* If positive bone marrow involvement at initial diagnosis the patient must have a negative bone marrow biopsy following R-chemotherapy to confirm the CR
Standard staging exams for patients with high-risk prostate cancer including bone scan or sodium fluoride (NaF) positron emission tomography (PET)/CT scan, and pelvic and prostate MRI
No distant metastases (M0) on bone scan or NaF PET/CT within 14 weeks prior to registration; equivocal bone scan findings are allowed if the physician determines that distant metastases are unlikely based on clinical judgment
Bone lesions: one or more osteolytic lesions on skeletal radiography, computed tomography (CT), or positron emission tomography-CT (PET-CT) OR
A bone scan and a CT or MRI abdomen/pelvis and chest x-ray (CXR) or chest CT scan, will have been performed within 12 weeks of treatment start; radiographic assessments will be selected by the attending physician as clinically indicated
Evidence of metastatic disease\r\n* NOTE: patients will not require baseline staging positron emission tomography (PET) or computed tomography (CT) chest, abdomen, pelvis or bone scan to rule out metastatic disease prior to enrollment; any staging scans will be ordered at the treating provider’s discretion; if metastatic disease is found on any staging studies done, patients will not be eligible for enrollment
ELIGIBILITY FOR TREATMENT ON ARM 1: Bi-dimensionally measurable disease by palpation, clinical exam, or radiographic imaging (X-ray, computed tomography [CT] scan, positron emission tomography [PET] scan, magnetic resonance imaging [MRI], or ultrasound)
Patients must have received baseline FDG-PET/CT +/- CT with contrast within 1 month +/- 2 weeks prior to study entry, and should have no contraindications to PET or CT imaging
Participants must have a diagnosis of multiple myeloma (MM) according Revised International Myeloma Working Group diagnostic criteria, which require the following findings,\r\n* Clonal bone marrow plasma cells >= 10% or biopsy-proven bony or extramedullary plasmacytoma and any one or more of the following myeloma defining events:\r\n** End organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically:\r\n*** Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the upper limit of normal or > 2.75 mmol/L (> 11 mg/dL)\r\n*** Renal insufficiency: creatinine clearance < 40 mL per min or serum creatinine > 177 umol/L (> 2 mg/dL)\r\n*** Anemia: hemoglobin value of > 20 g/L below the lower limit of normal, or a hemoglobin value < 100 g/L\r\n*** Bone lesions: one or more osteolytic lesions on skeletal radiography, computed tomography (CT), or positron emission tomography (PET)-CT\r\n** One or more of the following biomarkers of malignancy:\r\n*** Clonal bone marrow plasma cell percentage >= 60%\r\n*** Involved: uninvolved serum free light chain ratio >= 100\r\n*** > 1 focal lesions on magnetic resonance imaging (MRI) studies
clinical and laboratory signs: rapid disease progression, high standardized uptake value (SUV) (> 12) by positron emission tomography (PET) at baseline if PET scans are performed (optional).
There should be no evidence of metastatic disease on imaging of the chest, abdomen, and pelvis; this imaging should be either a contrast-enhanced computed tomography (CT) scan, or a contrast-enhanced magnetic resonance imaging (MRI) scan; positron emission tomography (PET) scans alone will not be adequate alternatives; there should be no evidence of occult metastatic disease in the abdomen, confirmed by laparoscopic examination
Measurable disease for phase IIa portion only \r\n* Lymphoma (includes CTCL patients who are without evidence of the disease in the skin): computed tomography (CT) or positron emission tomography (PET)/CT by modified Cheson criteria with incorporation of PET\r\n* CTCL: modified severity weighted assessment (mSWAT) > 0, or absolute Sezary count >= 1000 cells/uL
Histologic proof of stage II, III or IV melanoma that has been completely resected or completely treated with ablative therapy (ex: stereotactic body radiosurgery, radiofrequency ablation, cryoablation) with no current evidence of disease, as demonstrated by imaging within 2 months (61 days: stage IIIB, IIIC or stage IV; must be computed tomography [CT], magnetic resonance imaging [MRI], or positron emission tomography [PET]/CT) or 6 months (183 days: stage II or IIIA; may be chest x-ray, CT, MRI, or PET/CT)
Clinically determined to be clinically staged (American Joint Committee on Cancer [AJCC] 7th edition [ed.]) T3-4 N0 M0 or T any N1-2 M0 based upon the following minimum diagnostic workup within 90 days prior to registration:\r\n* Colonoscopy\r\n* History/physical examination (including medication history screen for contraindications)\r\n* Contrast-enhanced imaging of the abdomen and pelvis either by computed tomography (CT), magnetic resonance imaging (MRI), or whole body positron emission tomography (PET)-CT (preferred)\r\n* Chest x-ray (or CT) of the chest to exclude distant metastases (except for those who have had whole body PET-CT per above bullet point)\r\n* Transrectal ultrasound (TRUS) or MRI for T staging
No evidence of metastatic or nodal disease as determined by radionuclide bone scans computed tomography (CT)/MRI; non-pathological lymph nodes must be less than 20 mm in the short (transverse) axis
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by computed tomography (CT) scan, or for skin lesions not measurable by CT scan, measurements may be performed with caliper or flexible ruler\r\n* Note: stage IV no evidence of disease (NED) is excluded by this criterion
Staging studies with a computed tomography (CT) scan of the chest and abdomen and bone scan, or a positron emission tomography (PET)/CT is required for clinical stage III, and are considered optional for stage II breast cancers
Visceral metastases as assessed by chest, abdominal or pelvic computed tomography (CT) (or other imaging modality)
Appropriate stage for protocol entry based upon the following minimum diagnostic workup:\r\n* History/physical examination within 30 days prior to registration\r\n* Fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed tomography (CT) scan for staging within 60 days prior to registration\r\n* Magnetic resonance imaging (MRI) scan with contrast of the brain (preferred) or CT scan of the brain with contrast within 60 days prior to registration
Patients with at least one target lesion amenable to serial static and dynamic FLT-PET/CT imaging will be mandated to have correlative FLT-PET/CT imaging per the study schema for a target of 20 patients with a maximum of 30 patients
Radiographic evidence (computed tomography [CT], magnetic resonance [MR], or positron emission tomography [PET] CT) consistent with osseous metastatic disease on CT, MR, or PET CT obtained within 4 weeks of treatment will be used for pre-study treatment delivery; the gross tumor volume (GTV) of the target lesions will be determined from this radiographic study and must be =< 250 cubic centimeters\r\n* NOTE: patient is still eligible if a diagnostic image set is not available within 4 weeks of treatment if the patient will undergo a kilo voltage CT (kVCT) simulation in the Department of Radiation Oncology with contouring directly onto this image set
Any evidence of extraocular retinoblastoma clinically or by magnetic resonance imaging (MRI) of brain and orbits with and without gadolinium; MRI may be done within 21 days prior to study entry\r\n* Evidence of systemic metastases on bilateral bone marrow, lumbar puncture, bone scan (or fludeoxyglucose F-18 [FDG] positron emission tomography [PET] scan), and/or any other additional tests done at study entry; (Note: these tests are required only with specific indications for required observations)
Distant metastatic disease limited to peritoneum and radiologically occult (not visualized on preoperative imaging to include [computerized tomography] CT scan, ultrasound, [magnetic resonance imaging] MRI, positron emission tomography [PET]/CT): \r\n* Positive peritoneal cytology\r\n* Carcinomatosis on diagnostic laparoscopy or laparotomy
Detectable metastases by bone scan, CT-scan or MRI
For all patients a bone scan must be performed within 60 days prior to registration for tumor assessment; computed tomography (CT) scans (abdomen and pelvis) and chest x-ray are optional, but must be repeated if used for disease assessment; for late induction registrations, tumor assessment imaging showing metastatic disease must be available prior to start of androgen deprivation therapy
Patients can have up to only 6 discrete active extracranial lesions (=< 3 in the liver and =< 3 in the lung) identified by diagnostic computed tomography (CT) or positron emission tomography (PET)/CT scan or magnetic resonance imaging (MRI) within 8 weeks prior to the initiation of SBRT\r\n* For patients who have received prior radiotherapy to the primary site in the lung, residual PET activity is difficult to interpret and will not be considered a site of active disease if the CT appearance is stable or improved over an interval of at least three months\r\n* Patients who previously received radiotherapy to the primary site will be ineligible if there is CT evidence of disease progression within the past 3 months\r\n* Patients with previously un-irradiated primary sites will be potentially eligible, but special considerations apply\r\n* Up to 2 contiguous vertebral metastases will be considered a single site of disease
Positron emission tomography (PET)/CT, x-ray or CT-scan of chest showing no evidence of metastatic disease
PET/CT or CT-scan of the neck showing no evidence of nodal involvement
There must be documentation by PET/CT scan, CT scan, or MRI, that the patient has evidence of measurable metastatic disease per RECIST criteria.
Must have at least one bi-dimensionally measurable lesion ?1.5 cm) documented by CT scan.
Patients must have non-metastatic (M0) disease, as defined by a lack of metastases seen on computed tomography (CT) scan of the chest/abdomen/pelvis and whole-body radionuclide 99Tc (technetium-99) bone scan, (or sodium fluoride positron emission tomography [PET] scan) taken within 3 months of study entry
Imaging with positron emission tomography (PET) scan, computed tomography (CT) scan of the abdomen and pelvis, and/or magnetic resonance imaging (MRI) of the abdomen and pelvis must be performed and negative for metastatic disease within 12 weeks of enrollment
Evidence of metastatic disease on PET, CT, and/or MRI performed within 12 weeks of enrollment
CT or MRI of the neck with and without contrast; Note: a CT scan of neck and/or a PET/CT performed for the purposes of radiation planning may serve as planning tools
Evidence of underlying end organ damage and/or myeloma defining event attributed to underlying plasma cell proliferative disorder meeting at least one of the following:\r\n* Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) above upper limit of normal or >= 2.75 mmol/L (11 mg/dL)\r\n* Anemia: hemoglobin value < 10 g/dL or > 2 g/dL below lower limit of normal\r\n* Bone disease: >= 1 lytic lesions on skeletal X-ray, computed tomography (CT), or positron emission tomography (PET)-CT; for patients with 1 lytic lesion, bone marrow should demonstrate >= 10% clonal plasma cells\r\n* Clonal bone marrow plasma cell percentage >= 60%\r\n* Involved/un-involved serum free light chain ratio >= 100 and involved free light chain > 100 mg/L\r\n* > 1 focal lesion on magnetic resonance imaging study (lesion must be > 5 mm) in size
Absence of distant metastases on standard diagnostic work-up =< 10 weeks prior to registration; (chest computed tomography [CT], chest x-ray [CXR], positron emission tomography [PET]/CT, etc.)
Patients must have shown unequivocal radiographic evidence for tumor progression by MRI or CT scan; a scan should be performed within 14 days prior to registration and on a steroid dose that has been stable or decreasing for at least 5 days; if the steroid dose is increased between the date of imaging and registration a new baseline MR/CT is required; the same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement
No evidence of regional nodal or distant metastases based on computed tomography (CT) abdomen and pelvis and whole body bone scan within 120 days prior to study entry; nodes less than 1.5 cm will be considered reactive and biopsy is not required; nodes 1.5 cm or larger are required to undergo biopsy and be negative prior to study registration; bone scan findings in the absence of blastic or lytic lesion correlates on CT imaging will also be deemed non-neoplastic
Measurable disease with a lymph node or tumor mass ?1.5 cm in at least one dimension by CT, PET/CT or MRI.
Protein criteria must be present at diagnosis (quantifiable M-component of immunoglobulin [Ig]G, IgA, IgD, or IgE and/or urinary kappa or lambda light chain, Bence-Jones protein, or free kappa light chain or free lambda light chain) in order to evaluate response; non-secretory participants are eligible provided the participant has >= 20% plasmacytosis OR multiple (>= 3) plasmacytomas or lesions on magnetic resonance imaging (MRI) at the time of diagnosis or study enrollment, OR the presence of lesions on positron emission tomography (PET)/computed tomography (CT) scan or skeletal survey at diagnosis or study enrollment
Anatomic imaging (CT or MRI) of all sites of disease along with chest CT at baseline and restaging for all patients will be done to allow for assessment of RECIST progression. RECIST progression will determine progressive disease regardless of other imaging.
Histologically confirmed, metastatic prostate cancer (positive bone scan and/or measurable disease on CT scan and/or MRI of the abdomen and pelvis).
No evidence of metastatic disease as determined by chest computed tomography (CT) scan, abdomen/pelvis CT scan (or magnetic resonance imaging [MRI] with gadolinium and/or manganese); all patients must be staged with a physical exam, chest CT, abdominal CT with intravenous contrast (or abdominal MRI with gadolinium and/or manganese)
PRE-REGISTRATION INCLUSION CRITERIA: Histologically confirmed HER2-negative primary invasive ductal or invasive lobular breast carcinoma; for patients enrolling for neoadjuvant treatment, diagnosis must be clinical stage II or III; for patients enrolling for adjuvant treatment, diagnosis must be pathologic stage IIA to IIIC\r\n* Standard HER2 testing will be performed in the surgical specimen at Washington University according to the standard of care in the department of pathology; a HER2-negative primary breast cancer sample from a patient eligible for randomization should have a HER2 immunohistochemistry (IHC) score of 0 or 1+; those patients with IHC score of 2+ should be HER2 fluorescent in situ hybridization (FISH)-negative in standard testing\r\n* Patient will have undergone staging studies including a computed tomography (CT) of the chest/abdomen/pelvis and bone scan and/or positron emission tomography (PET) scan either prior to the initiation of treatment or prior to entry into the trial\r\n* In addition, patients with non-metastatic, HER2-negative, recurrent tumors who need chemotherapy are eligible
REGISTRATION EXCLUSION CRITERIA: Evidence of distant metastasis present by CT scan, bone scan, or physical exam
Fluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least 1.5 cm by CT
Known brain metastasis or evidence of metastatic disease by computed tomography (CT) scan, physical exam, or bone scan within 4 weeks of registration\r\n* Patients with equivocal uptake on a bone scan that in the clinician's opinion do not definitively constitute metastatic disease are eligible
Participants must not have metastatic disease; pre-operative chest CT scan is required within 10 weeks prior to registration; patients with overt evidence of lung metastatic disease are excluded from the study; however, because of the sensitivity/specificity of the chest CT, small incidental lesions without a histologic diagnosis may not be a basis for study exclusion
Metastatic disease as evidenced by the presence of soft tissue and/or bone metastases on imaging studies (computed tomography [CT] of abdomen/pelvis, bone scintigraphy)
Patients with DLBCL had a positive [18F]fluorodeoxyglucose-positron emission tomography (FDG-PET) scan at baseline (Cheson response criteria)
Patients must have radiological documentation of metastatic disease to the thoracic or lumbar spine which may include computer assisted tomography (CAT scan), positron emitted tomography (PET) or nuclear medicine bone scan (NMBS); magnetic resonance imaging (MRI) is required prior to treatment planning to confirm the extent of the disease and is used for defining the target for the radiation
Metastatic disease on bone scan and/or involvement of soft tissues (lymph nodes and/or viscera) by computed tomography (CT) scan, positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI)
Patients must have been evaluated by standard-of-care full body imaging studies (computed tomography [CT], positron emission tomography [PET]-CT or magnetic resonance imaging [MRI]) as part of the initial clinical work-up at baseline (no more than 4 weeks prior to study enrollment) and after completion of induction HDI-ipilimumab (at 6-8 weeks after the first dose of ipilimumab/HDI and prior to the definitive lymphadenectomy procedure)
No evidence of metastatic disease as determined by chest computed tomography (CT) scan, abdomen/pelvis CT scan (or magnetic resonance imaging [MRI] with gadolinium and/or manganese) within six weeks of study entry; all patients must be staged with a physical exam, chest CT, abdominal CT with intravenous contrast (or abdominal [abd] MRI with gadolinium and/or manganese)
Measurable disease as assessed by 2 dimensional measurement by computed tomography (CT) (> 2 cm or 1.5 cm if 0.5 cm slices are used, as in spiral CT scan)
Chemosensitive disease as defined by at least a partial response to salvage therapy by PET/computed tomography (CT) criteria
Measurable disease: lesions that can be accurately measured in at least two dimensions as >= 1.0 x 1.0 cm by computerized tomography (CT), PET/CT (positron emission tomography/CT), or magnetic resonance imaging (MRI)
No evidence of metastatic disease as determined by chest computed tomography (CT) scan, abdominal CT scan (or magnetic resonance imaging [MRI] with gadolinium and/or manganese) and staging laparoscopy; all patients must be staged with a physical exam, chest CT, abdominal CT with intravenous contrast (or abdominal MRI with gadolinium and/or manganese) and laparoscopy; only potentially resectable patients are eligible; potentially resectable is defined as \r\n* No extrapancreatic disease\r\n* No evidence (on CT) of involvement of the celiac axis or spinal muscular atrophy (SMA) \r\n* No evidence (CT or MRI) of occlusion of the superior mesenteric vein (SMV) or superior mesenteric-portal vein (SMPV) confluence, and \r\n* No evidence of gross peritoneal or distant metastases on staging laparoscopy or laparotomy
MRI of the pelvis and/or PET-CT within 4 months before registration
For patients with solid malignancies and lymphoma, radiographically detectable (either fludeoxyglucose-positron emission tomography [PET], computed tomography [CT] scan/magnetic resonance imaging [MRI] or bone scan) or measurable disease will be required; measurable disease is defined as at least one measurable lesion >= 10 mm on CT scan (15 mm for nodal lesions)
Glioma showing prior spontaneous hemorrhage as determined from the clinical history or from any preoperative computed tomography (CT) or MRI scan (excluding grade 1 punctate, incidentally found)
New or progressive pulmonary infiltrates on screening chest x-ray or chest computed tomography (CT) scan that has not been evaluated with bronchoscopy, if feasible; infiltrates attributed to infection must be stable/improving (with associated clinical improvement) after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections); surgical resection waives any waiting requirements
New or progressive pulmonary infiltrates on screening chest x-ray or chest computed tomography (CT) scan that has not been evaluated with bronchoscopy, if feasible; infiltrates attributed to infection must be stable/improving (with associated clinical improvement) after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections)
Patients must not have evidence of bone metastases or lymph node involvement as determined by bone scan or computed tomography (CT) scan of the abdomen and pelvis within 4 weeks of study entry; Note: NaF-PET/CT scan information will NOT be used to determine evidence of metastases for eligibility purposes or for defining disease progression
Baseline mammography prior to surgery is required; for patients with lymphatic involvement computed tomography (CT) scan of the chest, CT of the abdomen, and bone scan and/or positron emission tomography (PET)/CT scan are required prior to delivery of chemotherapy; for most patients, this will be months prior to radiation; for patients with low burden nodal disease only mammography prior to surgery will be required\r\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
Measurable disease defined as: \r\n* At least one non-nodal lesion whose longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with spiral computed tomography (CT) scan, >= 2 cm with CT component of a positron emission tomography (PET)/CT or magnetic resonance imaging (MRI); and/or\r\n* A lymph node whose short axis must be > 1.5 cm when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm); Note: tumor lesions in a previously irradiated area are not considered measurable disease; disease that is measurable by physical examination only is not eligible
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) or the CT portion of the positron emission tomography (PET)/CT: must have at least one lesion that has a single diameter of >= 2 cm or tumor cells in the blood >= 5 x 10^9/L; skin lesions can be used if the area is >= 2 cm in at least one diameter and photographed with a ruler
Patients must have no evidence of visceral or nodal metastatic disease proximal to the common iliac bifurcation on 2 view chest x-ray or computed tomography (CT) of the chest and abdominal-pelvic imaging with computerized tomography or magnetic resonance imaging (MRI) of the abdomen and pelvis; chest x-ray or CT of the chest and CT or MRI of the abdomen and pelvis must be obtained within 56 days prior to registration; positron emission tomography (PET)/CT may be used as an alternative to CT or MRI or to resolve possible areas of metastases seen on cross sectional imaging
These laboratory values must be obtained within 28 days prior to registration; patients with levels of one or more of these enzymes greater than institutional upper limit of normal (IULN) may still be enrolled if metastatic disease is excluded with appropriate imaging which may include dedicated liver imaging, bone scan, PET, CT, MRI, or biopsy when appropriate
Deauville score of 1-3 on post-chemotherapy (or interim) positron emission tomography (PET) scan
All lung lesions must be visible on computed tomography (CT) imaging
Subjects with evidence of recto?sigmoid involvement by pelvic examination or bowel involvement on\r\ncomputed tomography (CT) scan or clinical symptoms of bowel obstruction
Patients may have had one cycle only of ABVD prior to enrolling on study; no other prior treatment (chemotherapy or radiation therapy) for Hodgkin lymphoma is allowed; if patient has had one cycle of ABVD, in order to be eligible to enroll on Cancer and Leukemia Group B (CALGB) 50801, the patient must have had all of the following tests prior to starting the first cycle of ABVD:\r\n* Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multi gated acquisition (MUGA)\r\n* Pulmonary function tests (PFTs) (including diffusing capacity of the lung for carbon monoxide [DLCO]/forced vital capacity [FVC])\r\n* CT scan (neck**, chest, abdomen, pelvis)\r\n* FDG-PET/CT scan\r\n* Chest X-ray, posterior-anterior (PA) & lateral\r\n* Complete blood count (CBC), differential, platelets\r\n* Erythrocyte sedimentation rate (ESR)\r\n* Serum creatinine\r\n* Glucose\r\n* Aspartate aminotransferase (AST)\r\n* Alkaline phosphatase\r\n* Bilirubin\r\n* Lactate dehydrogenase (LDH)\r\n** Patients with a negative FDG-PET/CT scan do not need to have had a dedicated neck CT scan prior to starting the previous cycle of ABVD
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination within 30 days prior to registration;\r\n* Imaging of the primary tumor by MRI and/or computed tomography (CT) with and without contrast and/or positron emission tomography (PET)/CT within 60 days prior to registration;\r\n* Staging workup evaluated by chest CT and/or PET/CT showing no distant metastasis within 60 days prior to registration
Metastatic disease or regional lymph node involvement. Chest CT will be mandatory prior to enrollment to evaluate for the presence of metastatic disease. Pulmonary nodule(s) < 5 mm without a histological diagnosis may not be the basis for study exclusion given the lack of specificity of chest CT. If pulmonary nodule(s) > 5 mm are noted on chest CT but appear stable relative to prior chest imaging of at least 6 months duration, then this is permitted.
Residual FDG-PET activity defined as Deauville 4 or 5 on a PET-CT within 3 and 8 weeks post the last dose of front line therapy
>= 1 measurable disease site on computed tomography (CT) scan or positron emission tomography (PET) (> 1.5 cm in longest dimension); (in select cases, for example extremity lesions, a magnetic resonance imaging [MRI] may be substituted)
Evidence of underlying end organ damage and/or myeloma defining event attributed to underlying plasma cell proliferative disorder meeting at least one of the following:\r\n* Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) above upper limit of normal or >= 2.75 mmol/L (11 mg/dL)\r\n* Anemia: hemoglobin value < 10 g/dL or > 2 g/dL below lower limit of normal\r\n* Bone disease: >= 1 lytic lesions on skeletal X-ray, computed tomography (CT) or positron emission tomography (PET)-CT; for patients with 1 lytic lesion, bone marrow should demonstrate >= 10% clonal plasma cells\r\n* Clonal bone marrow plasma cell percentage >= 60%\r\n* Involved/un-involved serum free light chain ratio >= 100 and involved free light chain > 100mg/L\r\n* > 1 focal lesion on magnetic resonance imaging study (lesion must be > 5 mm) in size
No evidence of locoregional disease or distant metastases at screening. Subjects must have negative scans (CT, CT-PET or MRI) for locoregional recurrence, brain or lung metastases. A negative biopsy will be mandated in patients with a positive scan. Other evaluations should be performed as clinically indicated.
All oncologists and radiologists will review positron emission tomography (PET) scans prior to therapy as standard practice to confirm eligibility
All participants must have at least one bi-dimensionally measurable lesion (greater than [>]1.5 centimeters (cm) in its largest dimension by computed tomography [CT] scan)
Eligible patients will have biopsy (histology or cytology) proven non-squamous, NSCLC with stage IIIA or dry IIIB disease; patients with previously surgically resected NSCLC who have a locoregional recurrence that is clinically amenable to definitive treatment with chemoradiation are also eligible; previous diagnostic tissue may be accepted to confirm diagnosis and perform correlative studies; patients are still eligible if there is insufficient tissue for correlative studies; evidence of mediastinal nodal disease will be documented pathologically by pretreatment mediastinoscopy or EBUS/EUS, only if clinically indicated (i.e. if the staging computed tomography [CT] Scans and positron emission tomography [PET] Scans are equivocal)
Female patients with inoperable tumors or women with stage 4 disease diagnosed on computed tomography (CT), positron emission tomography (PET), PET/CT or bone scan
Baseline PET or PET/CT scans must show positive lesions compatible with CT-defined anatomical tumor sites (only applicable for FL, DLBCL, MCL, transformed indolent lymphoma, and FL transforming to DLBCL) CLL (Arms A and B):
No other signs of clinical recurrence or dissemination of prostate cancer as defined by normal CT-scan or MRI of the pelvis without local recurrence, and bone scan negative for metastases, and chest X-ray negative for metastases; prostascint scans will not be used to assess disease prior to study entry
Negative CT scans of the chest, abdomen, and pelvis within 6 months prior to enrollment to rule out possibility of metastases;
Patients must have the following within 4 weeks prior to registration:\r\n* Computed tomography (CT) chest with intravenous (IV) and oral agent\r\n* CT pelvis/abdomen with IV and oral agent\r\n* MRI brain with gadolinium\r\n* For patients with known bone metastases, elevated alkaline phosphatase or symptoms raising suspicion of bone metastases, a baseline bone scan is required
Histological documentation of local recurrence or metastasis is strongly encouraged, unless the risk of such a procedure outweighs the potential benefit of confirming the metastatic disease; if no histologic confirmation, then the metastases or recurrence will require documentation by a 2nd radiographic procedure (eg. PET/computed tomography [CT] scan or magnetic resonance imaging [MRI] in addition to the CT scan); if the imaging procedure does not confirm recurrent or metastatic disease, biopsy confirmation will be required
Patients must have clinical stage T1-T3a and no radiographic evidence of metastatic disease as demonstrated by:\r\n* EITHER computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen and pelvis, OR endorectal MRI of the pelvis that demonstrate no nodes > 1.5 cm\r\n* If one or more pelvic lymph node(s) measures > 1.5 cm, a negative biopsy is required; if more than one lymph node is > 1.5 cm, the largest or most accessible node should be biopsied; AND\r\n* Negative bone scan (with plain films and/or MRI and/or CT scan confirmation, if necessary)\r\nPositive positron emission tomography (PET) and ProstaScint scans are not considered proof of metastatic disease
Histologically or cytologically confirmed pancreatic adenocarcinoma that has metastatic disease measurable by computed tomography (CT), magnetic resonance imaging (MRI), or (positron emission tomography (PET)
Computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)/CT imaging of the chest, abdomen, and pelvic regions within 60 days prior to registration (for stage I patients, posteroanterior [PA] and lateral chest x-ray is sufficient for chest imaging)
Metastatic Disease with at least one lesion on bone scan and/or soft tissue on CT/MRI
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination =< 45 days prior to registration;\r\n* Computed tomography (CT) chest, CT or magnetic resonance imaging (MRI) or positron emission tomography (PET)-CT that includes abdomen and pelvis should be performed for initial radiological staging; this may be performed pre- or post-surgery =< 90 days prior to registration except in patients getting postoperative adjuvant chemotherapy, who will require CT, MRI or PET-CT including the chest and abdomen and pelvis no more than 30 days prior to registration; imaging performed postoperatively should show no evidence of residual disease
Every patient with relapse or progression into the CNS must be documented with computed tomography (CT) scan or MRI of the brain; other sites of relapse may be evaluated, including bone marrow
Measurable disease as assessed by 2 dimensional measurements by computed tomography (CT) (>= 1.5 cm)
Measurable disease by computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET) with at least one target lesion measuring 1.5 cm or larger
Patients must have an avid primary tumor with an standardized uptake value (SUV) of >= 5 on baseline (18F) FDG-PET/computed tomography (CT) imaging
Positron emission tomography (PET)/computed tomography (CT) is required for all patients, unless contraindicated; this may be acquired prior to study entry or after enrollment prior to SBRT planning
FDG PET-CT (disease) positive baseline scan with measurable disease.
Hypersplenism documented by imaging study (ultrasound [US] or computed tomography [CT])
Metastatic disease beyond the neck or supraclavicular area as demonstrated by positron emission tomography (PET)/CT or biopsy
Gross disease in the retrostyloid (high level II) or retropharyngeal lymph node regions by CT or PET/CT
History of diverticulitis (even a single episode) or evidence of diverticulitis at baseline, including evidence limited to computed tomography (CT) scan only; note: diverticulosis is not an exclusion criterion per se
Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:\r\n* History/physical examination within 30 days prior to registration \r\n* Assessment by medical oncologist who specializes in treatment of IHC within 30 days of registration \r\n* Pre-randomization scan (REQUIRED for all patients): computed tomography (CT) scan chest/abdomen/pelvis with multiphasic liver CT scan within 30 days prior to registration; if CT contrast is contraindicated, CT chest without contrast and magnetic resonance imaging (MRI) of abdomen and pelvis is permitted
Histologically proven adenocarcinoma of the prostate with evidence for skeletal metastases on bone scan and/or CT scan.
One or more measurable (> 1.5 cm in longest dimension) disease sites on CT (preferably PET/CT) or, if CT is contraindicated, MRI (preferably PET/MRI) scans.
Patients must be able to lie flat for at least 60 minutes and fit on a PET-CT scanner
Use of drugs to treat or prevent herpesvirus infections, including ganciclovir, acyclovir, valacyclovir, valganciclovir, foscarnet, cidofovir, and adefovir, must be stopped >= 24 hours prior to the baseline [124I]FIAU-PET-CT scan and cannot be resumed until after the last [124I]FIAU-PET-CT scan
Tumor is not clearly shown on a computed tomography (CT) scan
Have had a CT or MRI scan (chest, abdomen, pelvis and other suspected sites as applicable) to determine eligibility for randomization within 4 weeks prior to randomization (hereafter referred to as the \eligibility scan\)
Must have at least one site of disease (index lesion) measurable in two dimensions by computed tomography (CT)
Patients are eligible with untreated squamous, adenosquamous, or adenocarcinoma cancers of stage IB2-IVA carcinoma of the uterine cervix or stage II-IVA vaginal carcinoma not amenable to curative surgical resection; pathological verification of diagnosis must be obtained and recorded; the presence or absence of para-aortic lymph node metastasis will be based on pre-therapy 18F-FDG PET/CT; if the baseline 18F-FDG PET/CT identifies hypermetabolic para-aortic disease, such patients will not be eligible for participation; the patient must be able to tolerate the requirements for 18F-FDG PET/CT scanning
Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:\r\n* History/physical examination, including recording of pulse, blood pressure (BP), weight, and body surface area, within 45 days prior to registration\r\n* Whole body fludeoxyglucose-positron emission tomography (FDG-PET)/CT (orbits to mid-thighs) within 30 days prior to registration; PET/CT must be negative for distant metastasis\r\n* CT scan with contrast of the chest and upper abdomen to include liver and adrenals (unless medically contraindicated) within 30 days prior to registration\r\n* Magnetic resonance imaging (MRI) of the brain with contrast (or CT scan with contrast, if MRI medically contraindicated) within 30 days prior to registration
Bi-dimensionally measurable disease by palpation, clinical exam, or radiographic imaging (x-ray, computed tomography [CT] scan, positron emission tomography [PET] scan, magnetic resonance imaging [MRI], or ultrasound)
A subject with metastatic CRPC must have bone metastases accessible for biopsy by computed tomography (CT) guidance
No evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes on staging scans (computed tomography [CT] chest/abdomen/pelvis and bone scan or positron emission tomography [PET] scan)
Patients must have measurable disease on the 3D planning computed tomography (CT)
Patients with stage II disease and clinical suspicion for metastatic disease based on reported symptoms, physical examination findings, or laboratory abnormalities must have staging studies demonstrating no evidence of metastatic disease (with exception of axillary lymph nodes or mammary nodes); patients with stage III disease must have staging studies demonstrating no evidence of metastatic disease (with exception of axillary lymph nodes or mammary nodes), even if asymptomatic with normal physical examination and laboratory values; such staging studies must include: chest imaging (chest x-ray, computed tomography [CT], or MRI), abdominal/pelvis imaging (CT or MRI), and bone imaging (bone scan or positron emission tomography [PET]-scan); abnormalities that are indeterminate and too small to biopsy should be followed with further imaging, as appropriate, but do not exclude patients from the study; abnormalities that are suspicious and large enough to biopsy exclude patients from the study, unless a biopsy is performed and is negative for metastatic disease
Patient must have histologically proven primary or recurrent extremity melanoma, stage IIIB, IIIC, or stage IV (American Joint Committee on Cancer [AJCC] staging must be documented in patient’s medical record, as determined by computed tomography [CT] of the chest, abdomen and pelvis, and/or whole body positron emission tomography [PET] scan, and magnetic resonance imaging [MRI] of the brain within 4 weeks prior to administration of study drug)
Patients must have been evaluated by standard-of-care full body imaging studies (computerized tomography [CT], positron emission tomography [PET]-CT or magnetic resonance imaging [MRI]) as part of the initial clinical work-up at baseline (no more than 4 weeks prior to study enrollment) and after completion of induction nivolumab-ipilimumab or nivolumab alone (at 6-8 weeks after the first dose of induction and prior to the definitive surgery procedure)
Fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET).
Fluorodeoxyglucose positron emission tomography (FDG-PET) avid disease on baseline scan For enrollment in part 2, patients must meet all of the following:
No evidence of metastatic disease as determined by chest computed tomography (CT) scan, and abdominal CT scan (or magnetic resonance imaging [MRI] with gadolinium and/or manganese); all patients must be staged with a physical exam, chest CT, abdominal CT with intravenous contrast (or abdominal MRI with gadolinium and/or manganese)
Measurable disease by computed tomograph (CT)/ and/or positron-emission tomography CT (PET-CT)
Patients must have pathologic diagnosis of non-small cell lung carcinoma (NSCLC), by either histologic biopsy, or cytologic evidence; highly suspicious cytology (i.e. abnormal cells suspicious for malignancy) is acceptable, in the setting of a strongly positive computed tomography (CT)/positron emission tomography (PET) (standardized uptake value [SUV] > 5.0)
Patients must be considered an appropriate candidate for stereotactic body radiation therapy (SBRT); this is determined on an individualized basis, by the prospective multidisciplinary tumor board, that includes representation from surgical, radiation and medical oncology; criteria for appropriateness for SBRT include all of the following: but:\r\n* Stage I/II non-small cell lung carcinoma (NSCLC) – no evidence of distant metastases (patients with up to three lung nodules may be considered to have ‘multiple primary’ lung cancer rather than metastatic lung cancer and thus will be eligible; if a lymph node(s) >= 2 cm and/or PET-SUV >= 4.0 is identified, biopsy must be performed (and be negative) for the patient to be eligible; patients thought to have M1b disease, or malignant pleural/pericardial effusions are not eligible\r\n* Staging including CT chest, PET/CT must be up-to-date, i.e. within 6 weeks prior to registration; brain imaging (contrast-enhanced magnetic resonance imaging [MRI] or CT) is suggested for all patients, but is only mandatory for patients with abnormal neurologic exam\r\n* Tumor size =< 7 cm in greatest dimension based upon an up-to-date CT (and/or CT/PET) within 6 weeks prior to enrollment onto the study; radiation therapy treatment planning imaging is acceptable)\r\n* The patient must not be a candidate for (or declines because of high risk) surgical resection because of medical comorbidity/risk; the patient must have undergone an evaluation by an experienced thoracic surgeon within 12 weeks prior to registration; standard justification criteria may include forced expiratory volume in 1 second (FEV1) < 40% predicted; predicted postoperative FEV1 =< 30% predicted; diffusing capacity of the lung for carbon monoxide (DLCO) =< 60% predicted; pulmonary hypertension (estimated >= 40 mm Hg); poor cardiac function (ejection fraction [EF] =< 40%); Medical Research Council (MRC) dyspnea scale >= 3 (corresponds to inability to walk at least 100 yards without rest); baseline hypoxemia (partial pressure of oxygen [pO2] =< 55 mg HG and/or pulse oxygen [ox] < 88%), baseline hypercapnea (carbon dioxide [CO2] >= 45 mm Hg; there are also other, less objective criteria, including severe end-organ damage from diabetes/hypertension, severe atherosclerotic disease (heart, brain, aorta, peripheral artery)\r\n* Tumor(s) must be in a location/configuration such that risk of fistula is considered relatively low; this means that there can be no evidence of tumor invasion of a major (lobar/hilar) pulmonary vessel(s), aorta, vena cava, trachea or mainstem bronchus or esophagus; additional studies may be needed to assess this, including CT angiogram, MRI, bronchoscopy, esophagoscopy
At least 1 unresectable lesion on a CT (Computerized Tomography) scan that is measurable as defined by RECIST, Version 1.1
Systemic staging including computed tomography (CT) that covers the chest, liver and adrenal glands or a positron emission tomography (PET)/CT; magnetic resonance imaging (MRI) of the brain is required and must be negative for metastatic spread; if a patient is unable to tolerate MRI or has a contraindication to MRI, a head CT scan with and without contrast is acceptable
The tumor must be deemed as being borderline resectable; final computed tomography (CT) confirmation of surgical staging/eligibility will be at the discretion of the pancreatic surgeon of the patient
Baseline fludeoxyglucose F 18 (FDG)-positron emission tomography (PET) scans must demonstrate positive lesions compatible with computed tomography (CT) defined anatomical tumor sites\r\n* CT scan showing at least:\r\n** 2 or more clearly demarcated lesions/nodes with a long axis > 1.5 cm and short axis >= 1.0 cm OR\r\n** 1 clearly demarcated lesion/node with a long axis > 2.0 cm and short axis >= 1.0 cm
Patients should have measurable disease defined as a minimum of one tumor measuring >= 10 mm on computed tomography (CT) scans
Imaging features worrisome for malignancy (heterogeneous tumor, presence of calcifications, necrosis, > 10 Hounsfield units on an unenhanced CT scan, and delayed washout of contrast)
There must be an interval of at least 12 weeks from the completion of radiotherapy to start of device treatment; when the interval is less than 12 weeks from the completion of radiotherapy, the histological confirmation of progression must be unequivocal per Revised Assessment in Neuro-Oncology (RANO) criteria; the use of positron emission tomography (PET) scan, perfusion imaging, and magnetic resonance (MR) spectroscopy to differentiate between true early progression and pseudoprogression prior to biopsy or resection of probable recurrent tumor is per standard of care
Subjects must have cytologically or histologically confirmed ovarian, primary peritoneal or fallopian tube cancer.. In addition, subjects must have a tumor that is at least 1 cm in a single dimension and is radiographically apparent on CT, PET-CT or MRI (i.e., RECIST version 1.1 measurable disease).
Stage IV disease as evidenced by soft tissue, visceral and/or bony metastasis must be Response Evaluation Criteria in Solid Tumors (RECIST) evaluable on computed tomography (CT) scan and/or bone scan
No evidence of metastatic disease on imaging by whole body bone scan (technetium-99 or sodium fluoride [Na-F] positron emission tomography [PET] bone scan) and cross-sectional imaging of the abdomen/pelvis (computed tomography [CT] or magnetic resonance imaging [MRI]) within 6 weeks of day 1 of protocol therapy
Patients must have a diagnostic quality contrast computed tomography (CT) scan of the chest, abdomen and pelvis OR baseline positron emission tomography (PET)-CT scan performed within 28 days prior to registration
Evidence of tumor progression by MRI or computed tomography (CT) scan following radiation therapy or following the most recent anti-tumor therapy; note: patients who have had surgical treatment at recurrence are eligible if they had a resection with measurable or non-measurable residual disease on postoperative imaging or if there is imaging evidence of disease progression as compared to the first postoperative scan
Measurable, 18F-deoxyglucose (FDG)-avid (Deauville score ? 3) systemic disease (using Lugano Classification response criteria) by positron emission tomography (PET)-diagnostic computed tomography (CT). Baseline scans must be of acceptable quality to the central radiology laboratory prior to Cycle 1 Day 1.
Evidence of metastatic disease on bone scan or MRI/computed tomography (CT)
Stage clinical T1 N0 M0 or T2 N0 M0 as per American Joint Committee on Cancer (AJCC) Staging system 7th edition, based on the following criteria:\r\n* Chest computed tomography (CT) with upper abdomen to include the liver and adrenal glands with intravenous (IV) contrast (unless medically contraindicated) within 2 months of registration\r\n* Participants must have measurable disease, defined as >= 5 mm on a diagnostic CT scan with slice thickness of no more than 2.5 mm\r\n* Positron emission tomography (PET)/CT scan including neck, chest, abdomen, pelvis within 2 months of study enrollment characterizing the primary tumor and documenting the absence of nodal and distant metastasis\r\n* Brain magnetic resonance imaging (MRI) with gadolinium within 2 months of study enrollment demonstrating the absence of brain metastasis; if an MRI is medically contraindicated or if the patient refuses, a head CT with IV contrast is acceptable
Centrally located, defined as located within 2 cm of the central bronchial tree (carina, right and left main bronchi, right and left upper lobe bronchi, bronchus intermedius, right middle lobe bronchus, lingular bronchus, right and left lower lobe bronchi), major vessels (aorta, pulmonary artery trunk, left/right pulmonary artery/vein main branches, superior/inferior vena cava, brachiocephalic artery trunk or left/right brachiocephalic vein, left/right subclavian artery/vein), esophagus, heart, tracheal, pericardium, mediastinal pleural and brachial plexus, chest wall and vertebral body, but no direct invasion, stage I (T1-T2a =< 5 cm without main bronchus involvement), selective stage II (selective T3 with involvement of mediastinal pleura, parietal pericardium), based upon the following minimum diagnostic workup:\r\n* History/physical examination including weight and assessment of Zubrod performance status within 2 months prior to registration\r\n* Evaluation by an experienced thoracic cancer clinician within 2 months prior to registration\r\n* Computed tomography (CT) scan with intravenous contrast (unless medically contraindicated) of the entirety of both lungs and the mediastinum, most part of liver, and adrenal glands acquired within 2 months prior to registration must be available; the primary tumor dimension will be measured on the CT in lung window; if positron emission tomography (PET)/CT scan is performed within 2 months prior to registration, CT of chest is recommended but not required; whole body fluorodeoxyglucose (FDG)-PET within 3 months prior to registration with adequate visualization of the primary tumor and draining lymph node basins in the hilar and mediastinal regions and adrenal glands; pulmonary function tests (PFTs): routine spirometry, lung volumes, diffusion capacity (within 3 months prior to registration)\r\n* Patients with hilar or mediastinal lymph nodes =< 1 cm and no abnormal hilar or mediastinal uptake on PET will be considered N0; patients with > 1 cm hilar or mediastinal lymph nodes on CT or abnormal PET (including suspicious but non-diagnostic uptake) may still be eligible if directed tissue biopsy of all abnormally identified areas are negative for cancer; the primary tumor should be considered medically inoperable by an experienced thoracic cancer clinician for a standard lobectomy and mediastinal lymph node dissection/sampling procedure or patient refuses surgery; the patient may have underlying physiological medical problems that would prohibit a surgery due to a low probability of tolerating general anesthesia, the operation, the postoperative recovery period, or the removal of adjacent functioning lung; these types of patients with severe underlying health problems are deemed \medically inoperable;\ standard justification for deeming a patient medically inoperable based on pulmonary function for surgical resection of NSCLC may include any of the following: Baseline forced expiratory volume of the lung in 1 second (FEV1) < 50% predicted, postoperative FEV1 < 30% predicted, severely reduced diffusion capacity, baseline hypoxemia and/or hypercapnia, exercise oxygen consumption < 50% predicted, severe pulmonary hypertension, diabetes mellitus with severe end organ damage, severe cerebral, cardiac, or peripheral vascular disease, or severe chronic heart disease; if the patient has medically resectable/operable disease but declines surgery after consulting with a thoracic surgeon, he/she will be considered eligible
The presence of metastatic disease amenable to computed tomography (CT) or ultrasound guided biopsy; this may include thoracolumbar vertebral bodies, pelvis, femur or humerus, or soft tissue or nodal metastasis amenable to biopsy (excluding lung or pleural lesions)
Patients must have measurable disease > 1.5 cm evidenced by computed tomography (CT) scan of the neck/chest/abdomen(abd)/pelvis or CT/positron emission tomography (PET) scans
Measurable or assessable disease defined as at least one of the following:            \r\n* A lymph node or tumor mass that is >= 2.0 cm in at least one dimension by computed tomography (CT) portion of positron emission tomography (PET)/CT scan, CT scan, or magnetic resonance imaging (MRI)\r\n* Diffuse infiltration of an organ such as the stomach, bone marrow, peripheral blood, liver, lungs, or bowel by lymphoma without a discrete mass would constitute assessable, but not measurable, disease
Fluorodeoxyglucose-avid and measurable disease of at least 1.5 cm as documented by both positron emission tomography and spiral computed tomography.
A baseline scan should be performed within 14 days prior to registration and on a steroid dosage that has been stable for at least 5 days otherwise a new baseline MR/CT is required; the same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement
Patients must have failed prior external beam radiation therapy; a positron emission tomography (PET) or thallium single photon emission computed tomography (SPECT), MR spectroscopy and MR perfusion, or surgical documentation may be done at the discretion of the treating physician if there is a question of radiation changes/necrosis versus progressive disease
All patients must have undergone staging of their lung cancer prior to enrollment with a chest CT scan and PET scan, both within 8 weeks of inclusion, in addition to bronchoscopy
cT3 or cT4
Have no evidence of distant metastases (as determined by endoscopic ultrasound [EUS], PET-computed tomography [CT] or staging laparoscopy)
Post-operative computed tomography (CT) scan of the chest, abdomen, and pelvis =< 30 days prior to registration demonstrating no evidence of residual or recurrent malignancy
Positron emission tomography (PET) avid disease with standard uptake value (SUV) > 5
Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 10 mm with computed tomography (CT) scan, as >= 20 mm by chest x-ray, or >= 10 mm with calipers by clinical exam; PET/CT scan is acceptable as a substitute for a CT scan if the CT portion of the PET/CT is of identical diagnostic quality to a diagnostic CT scan
Measurable disease (at least 1 lesion of >= 1.5 cm in diameter) as detected by computed tomography (CT) or the CT images of the positron emission tomography (PET)/CT
No clinical evidence of N1, N2 or N3 lymph nodes as assessed by CT and/or PET-CT
Computed tomography (CT) of the neck to confirm staging
CT scan chest, abdomen and pelvis or positron emission tomography (PET)/CT scan (diagnostic quality CT) performed within 28 days of study registration; for disease outside the brain, tumors must be > 10 mm by CT scan
Measurable disease by Non-Hodgkin’s Lymphoma Response Criteria on FDG-PET/CT; baseline measurements and evaluations must be obtained =< 21 days prior to registration
Patients must have no evidence of metastasis on positron emission tomography (PET) scan or magnetic resonance imaging (MRI) or computed tomography (CT) scan of the pelvis and chest imaging
Radiographic evidence of radiation pneumonitis on a computed tomography (CT) scan of the chest with or without contrast
Patients with any radiographic evidence of metastases, including plain x-ray, bone scan, computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, or positron emission tomography (PET) scan
Fludeoxyglucose F-18 (FDG)-avid disease by FDG-PET/computed tomography (CT)
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; contrast-enhanced computed tomography (CT) scans of the neck, chest, abdomen and pelvis are required; a whole body positron emission tomography (PET)/CT scan with diagnostic quality images and intravenous iodinated contrast may be used in lieu of a contrast enhanced CT of the chest, abdomen and pelvis; imaging of the head and neck is required only if the patient has a head/neck primary; contrast may be omitted if the treating investigator believes that exposure to contrast poses an excessive risk to the patient; if skin lesions are being followed as measurable disease, photograph with a ruler included and physician measurements, must be kept in the patients chart as source documentation; all measurable lesions must be assessed within 28 days prior to registration; tests to assess non-measurable disease must be performed within 42 days prior to registration; all disease must be assessed and documented on the baseline tumor assessment form (RECIST 1.1)
No evidence of metastatic disease as determined by radionuclide bone scans and computed tomography (CT)/MRI; lymph nodes must be less than 20 mm in the short (transverse) axis
Patients must have cross-sectional body imaging (positron emission tomography [PET]-computed tomography [CT] or equivalent) performed within 4 weeks of study enrollment and available for review
Positive 4 dimensional computed tomography (4D CT) for single gland (adenoma) primary hyperparathyroidism
Patient has inability to tolerate 4D CT scan (for example; contrast intravenous [IV] allergy, claustrophobia, renal disease)
Radiographic evidence* of bone metastases within 8 weeks of study for non-weight bearing sites and 4 weeks for weight bearing sites; the patient must have pain which appears to be related to the radiographically documented metastasis in the opinion of the treating physician, and the decision has been made by the responsible clinician that a course of palliative external beam radiation therapy is appropriate treatment; multiple sites eligible if they can be included in no greater than 3 treatment sites and not all identifiable lesions will require treatment unless they are painful lesions\r\n* This should be one of the following:  plain film, bone scan, positron emission tomography (PET) scan, computed tomography (CT) scan, or magnetic resonance imaging (MRI)
Scheduled for low dose computed tomography (CT) screening for lung cancer
Chest radiograph or computed tomography (CT) scan within =< 3 months prior to study enrollment rules out primary or metastatic malignancy in the lungs or pleural space as a significant cause of respiratory insufficiency
Presence of cT1 renal mass by diagnostic computed tomography (CT) assessment
Uncontrolled infections, defined as positive blood cultures within 72 hours of study entry, or evidence of progressive infection by imaging studies such as chest computed tomography (CT) scan within 14 days of registration
Fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) avid tumors
The patient must have localized spine metastasis from the cervical (C)1 to lumbar (L)5 levels by a screening imaging study (bone scan, positron emission tomography [PET], computed tomography [CT], or MRI) (a solitary spine metastasis; two separate spine levels; or up to 3 separate sites [e.g., C5, thoracic (T)5-6, and T12] are permitted;) each of the separate sites may have a maximal involvement of 2 contiguous vertebral bodies; patients can have other visceral metastasis, and radioresistant tumors (including soft tissue sarcomas, melanomas, and renal cell carcinomas) are eligible
The patient has received a clinical classification of stage I or II disease; \clinically classified\ means using all studies including computed tomography (CT) scans, positron emission tomography (PET) scans, bone scans, mediastinoscopy, and/or any study or procedure performed short of thoracotomy
After completion of radiotherapy, within the last 12 months, a positron emission tomography (PET)/computed tomography (CT) or contrast-enhanced CT scan must be performed within 8 weeks of registration demonstrating no evidence of disease or loco-regional recurrence
Referred for computed tomography (CT) guided biopsy of lung lesion
Measurable disease >= 1.5 cm as measured on positron emission tomography (PET)-computed tomography (CT) scan
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, defined as at least one lesion that can be accurately measured in at least one dimension >= 10 mm (>= 1 cm) by computed tomography (CT) imaging or magnetic resonance imaging (MRI) within 28 days prior to start of protocol therapy; the CT from a combined positron emission tomography (PET)/CT may be used if it is of diagnostic quality; laboratory parameters are not acceptable as the only evidence of disease
No evidence of any lymph node spread or distant metastases as determined by positron emission tomography (PET) computed tomography (CT) imaging within 16 weeks of enrollment; alternatively, for those without PET CT capability, a magnetic resonance imaging (MRI) or CT of the abdomen and pelvis and a chest x-ray confirming no evidence of metastatic disease is acceptable
Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to registration; at a minimum, chest x-ray is required; CT imaging of the chest or PET/CT is acceptable
Inability to tolerate po; patients who have a computed tomography (CT) scan with contrast dye within 7 days and/or have a pacemaker will be excluded from having a dual energy x-ray absorptiometry (DEXA) scan only
Measurable disease (or nonmeasurable bone-only disease) assessed by computed tomography (CT) or positron emission tomography (PET)/CT, performed as part of standard of care, at the discretion of the attending oncologist
Subjects must have had a baseline scan (computed tomography [CT], magnetic resonance imaging [MRI], or positron emission tomography-computer tomography [PET/CT]) of the chest to assess disease burden before starting on first line chemotherapy for NSCLC and those images must have been reviewed by the investigator prior to randomization. If the scan was performed more than 28 days prior to randomization, an additional scan must be performed and reviewed by the investigator to confirm that the patient has not progressed before randomization.
Patients must have had a contrast-enhanced computerized tomographic (CT) scan of the chest and abdomen within 2 months of study entry and be willing to have a follow up scan within 2 months of the completion of the retreat
Administered IV x-ray contrast medium ? 24 hours prior to the date of study PET/CT
Administered oral contrast medium ? 120 hours prior to the date of study PET/CT
Cytotoxic chemotherapy within 4 weeks of first planned study PET/CT scan
Filgrastim (G-CSF) therapy within 10 days of the first planned research PET/CT scan
No evidence of relapsed or residual malignancy within 30 days of trial entry; all patients must undergo appropriate staging for their malignancy (i.e. bone marrow aspiration for the leukemias and positron emission tomography [PET]-computed tomography [CT] scanning for the lymphomas); evidence of a persistent cytogenetic abnormality will constitute evidence of residual or relapsed disease in the leukemias, where present; individuals with chronic lymphocytic leukemia (CLL) are eligible if there is no more than 20% residual leukemia in the bone marrow at the time of study entry
Computed tomography (CT) scan of the chest done =< 6 months prior to pre?registration showing either negative findings (no nodules) or solid or part?solid nodules < 6 mm in size (consistent with < 1% probability of malignancy, Lung?Reporting and Data Systems [RADs] version 1.0)
Willing and able to undergo low dose computed tomography (CT) scan, as determined by radiology team, or has had a lung cancer screen within 30 days of enrollment into this protocol.
NHL\r\n* No clinical evidence of disease or disease-related symptoms\r\n* Typically fludeoxyglucose (FDG)-avid lymphomas: a post-treatment residual mass of any size is permitted as long as it is positron emission tomography (PET) negative\r\n* Variably FDG-avid lymphoma/FDG avidity unknown: all lymph nodes normal size by computed tomography (CT)\r\n* Spleen and liver non-palpable and without nodules\r\n* If pretreatment bone marrow biopsy was positive, repeat bone marrow biopsy must be negative; if morphologically indeterminate, immunohistochemistry should be negative
Evidence of progressive disease by imaging modalities or biopsy - persistent positron emission tomography (PET) activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of computed tomography (CT) changes indicating progression
STUDY I: Smoked at least one cigarette per week prior to undergoing the CT scan
Smoking history >= 20 pack/years; subjects must be included in an ongoing annual screening with low dose CT scan or must have two consecutive CT outside the context of a screening program confirming subsolid nodules
All nodules should be persistent at least after three months follow up with 1 dimension (1d)-CT; a reduction up to 15% of the diameter of the largest target nodule from the previous CT scan is allowed
Subject must have positron emission tomography (PET)-positive disease as per Lugano Classification
Bone lesions (1 or more osteolytic lesions on low-dose whole body computed tomography [LDCT], positron-emission tomography with computed tomography [PET-CT] or CT)
Patient must be able to lie still for a 20-30 minute PET/CT scan
Patient must NOT weigh more than the maximum weight limit for the table for the PET/CT scanner at the institution where the study is being performed
Patients must be able to lie still for a 1.5 hour PET scan
Patient must NOT weigh more than the maximum weight limit for the PET/CT table for the scanner(s) to be used at each center
Radiologic evidence of local recurrence or new or progressive metastatic disease demonstrated on anatomical imaging (CT, MRI, or ultrasound), whole-body bone scan (99m-Tc-MDP or Na-18F) within 4 weeks of enrollment.
COHORT I: Patient must be able to tolerate PET/CT imaging
COHORT I: Patient must not have claustrophobia that would preclude PET/CT imaging or other contraindications to CT imaging
CT or magnetic resonance (MR) scan of abdomen and pelvis which does not suggest presence of metastatic disease outside of the pelvis
Inability to undergo anti-3-[18F]FACBC PET-CT
N2 lymph nodes negative on positron emission tomography (PET) scan or mediastinoscopy
Patient must have perfusion CT target lesion (e.g., >= 1 cm in both the long and short axis, at least one half of the tumor appears enhancing and solid on a contrast-enhanced scan or has an attenuation of >= 10 Hounsfield unit [HU] on the unenhanced CT scan) on a contrast-enhanced conventional CT
Eligibility of a perfusion CT target lesion must be confirmed by the ACR Core Lab prior to study enrollment and the T0 perfusion CT scan
Patients unable to tolerate a SPECT/CT 99mTc-SC scan
Have a primary diagnosis, or at high clinical suspicion, of lung nodule(s) warranting surgery based on CT and/or PET imaging
Participants must have no evidence of nodal involvement (N0) or distant metastases (M0) on staging studies, which may include positron emission tomography (PET), computed tomography (CT), and/or mediastinoscopy
Scheduled for or completed a 18F-FDG-PET or 18F-FDG-PET/CT tumor staging procedure
Treating radiation oncologist intends to incorporate 68Ga-PSMA-11 PET/CT findings into the radiotherapy plan if patient undergoes 68Ga-PSMA-11 PET/CT.
Prior prostate-specific membrane antigen (PSMA) PET/CT.
Androgen deprivation therapy (ADT) within 3 months before 68Ga-PSMA-11 PET/CT.
Patients with known or suspected neuroblastoma or pheochromocytoma are eligible. 18F-DA PET/computed tomography (CT) scanning will not be the initial imaging study in a newly diagnosed patient
Axumin PET/CT scan already performed or scheduled as best standard of care procedure for suspected disease relapse within 2 weeks before or after intended 68Ga-PSMA-11 PET/CT
Any change in prostate cancer treatment between Axumin and 68Ga-PSMA PET/CT scan
Unable to lie flat, still or tolerate a PET scan
Whole body 18F-FDG PET/computed tomography (CT) or I-131 scintigraphy within the past 90 days of the scheduled 68Ga-PSMA PET demonstrating uptake
Cohort A only: Presence of at least three distinct metastatic lesions by standard imaging including whole body bone scan + cross-sectional imaging of the abdomen and pelvis obtained within 12 weeks prior to protocol scan
Participant must have undergone a PET/computed tomography (CT) examination with injection of a standard dose of 18F-fluorodeoxyclucose (FDG) or other PET tracer with a half-life greater than one hour either for clinical or research purposes within 3 hrs of the proposed PET-MRI examination
Unable to lie flat, still or tolerate a PET scan
Unable to lie flat, still or tolerate a PET scan
Patient must be able to lie still for a 20 to 30 minute PET/CT scan
Ability to undergo standard PET imaging; an 18 F FDG PET/CT scan will take place within 8 weeks of enrollment
Have a measurable lesion in the pelvis or abdomen, at a minimum of 0.5 cm in diameter on standard of care pre-operative imaging studies (computed tomography [CT], magnetic resonance imaging [MRI] or positron emission tomography [PET] scan)
Documented results from (or scheduled to undergo) CT or MRI of the chest, abdomen and pelvis as a SOC procedure within 28 days of baseline investigational 11C-Gln PET/CT and 18F-FSPG PET/CT
At least one lesion measurable according to PET Response Criteria in Solid Tumors (PERCIST) v1.0: > 2 cm in diameter to avoid PET partial volume effects
SUB-STUDY I: Unable to lie flat during or tolerate PET/CT
SUB-STUDY II: Unable to lie flat during or tolerate PET/CT
SUB-STUDY III: Imaging evidence of suspected metastatic disease, including CT, bone scan, MRI, ultrasound or other PET modalities
SUB-STUDY III: Unable to lie flat during or tolerate PET/CT
Any condition that precludes the proper performance of PET and/or CT scan: a) Subjects who are not able to tolerate the CT contrast agent, b) Subjects with metal implants or arthroplasty, or any other objects that might interfere with the PET and/or CT analysis, c) Subjects unable to raise arms for prolonged imaging purposes, d) Subjects unable to lie still for the entire imaging time, e) Subjects weighing greater than 110 kg (243 lb)
Patient weight exceeds table limit for the PET/CT scanner (400 pounds)
Patients with a body weight of 400 pounds or more, or a body mass index (BMI) which precludes their entry into the bore of the PET/CT scanner, because the findings will probably be compromised in image quality with CT, PET/CT and MRI.
Patients who cannot undergo PET/compute tomography (CT) scanning
Patients cannot undergo CT examination.
Subject must have been referred for a clinically indicated PET-computed tomography (CT)
Patient is able to remain still for duration of imaging procedure (approximately 30 minutes total for digital PET/CT)
Undergone standard of care conventional imaging (computed tomography [CT] and/or magnetic resonance [MR]; bone scan and/or sodium fluoride [NaF] PET)
Patient must be able to lie still for a 20 to 30 minute PET/CT scan.
Patients scheduled and approved for contrast enhanced CT that includes imaging of the abdomen and pelvis following the Department of Radiology standard of care protocol
Patients who have a history of serious adverse events related to a previous MRI or PET/computed tomography (CT)
Unable to lie flat, still or tolerate a PET scan
Diagnostic CT or MRI as part of the PET study or performed within one month of PSMA PET
Presence of at least one target lesion detected by standard staging scans that, in the judgment of study investigators, would be amenable to hyperpolarized C-13 pyruvate/metabolic MR imaging:\r\n* Soft tissue/visceral organ target lesions must measure at 1 cm in long axis diameter on computed tomography (CT) or MRI\r\n* Target lesions in the bone must be visualized by CT or MRI (lesions present only on bone scan do not qualify)\r\n* For patients with target lesion in prostate/prostatic bed:\r\n** No contra-indications to endorectal coil insertion (e.g., patients with a prior abdominoperineal resection of the rectum or latex allergy).\r\n** No prior local treatment to the selected lesion; patients who have received prior radiation or ablative therapy to the prostate will be required to have biopsy-proven evidence of disease recurrence following completion of local therapy
Subjects must have a computed tomography (CT) scan of the chest within 8 weeks of surgery
Previously imaged with 18F-DCFPyL PET/CT on >= 2 occasions as part of this or other study protocols
Agreed to FLT-PET imaging and signed consent and eligible FLT-PET protocol 2006-127
Patients with NSCLC diagnosis who have been referred for a clinical FDG PET/CT staging scan as part of their standard of care
Patient must have a PET/CT obtained within 40 days of having the EBUS-TBNA
No evidence of metastatic disease on conventional imaging, including a negative bone scan for skeletal metastasis and/or negative cross section imaging (MR or CT)
No evidence of metastatic disease on conventional imaging, including a negative bone scan for skeletal metastasis and negative contrast-enhanced CT; sodium fluoride (NaF) PET CT can substitute for separate bone scan and CT
Inability to undergo or cooperate with PET/computed tomography (CT) scan (e.g., claustrophobia)
Able to complete a PET/CT scan without the use of sedation
The time interval between 18F FSPG PET/CT and standard of care imaging (ie, 18F FDG PET/CT, diagnostic CT, or MRI) should be within 4 weeks (exceptions will be allowed for 6 weeks, if there are no other options)
Ideally, there should be no chemotherapy, radiotherapy, or immune/biologic therapy or biopsy between other imaging (PET/CTs, MRI, or diagnostic CTs) and 18F FSPG PET/CT scheduled or performed (exceptions by investigator discretion)
Claustrophobia interfering with MRI and PET/CT imaging
Inability to lie in the PET/CT scanner for the time required for scanning, up to 1 hour and 15 minutes (min) at a time and possibly with arms raised above the head for lung imaging
Unable to tolerate up to 60 min of PET imaging per imaging session
The patient must provide informed written consent, which will include a layman’s explanation of the estimated amount of additional radiation that the patient will receive from the investigational PET/CT scan using 18F-FSPG
Patients with a body weight of 400 pounds or more or a body habitus or disability that will not permit the imaging protocol to be performed, due to the compromise in image quality on both CT and PET/CT; if the standard-of-care 18F-FDG/PET was of diagnostic in quality as determined by the official clinical interpretation, then this will be presumptive evidence that the patient’s body habitus and/or disabilities should not prevent a diagnostic quality 18F-FSPG PET/CT scan, either
A recognized active lung infection (this will confound the standard-of-care 18F-FDG PET/CT scan)
Peptide receptor radionuclide therapy (PRRT) within 4 weeks of Ga-68 DOTATOC PET/CT scan
Patients with distant metastatic disease beyond N1 (regional) lymph nodes on conventional imaging studies (computed tomography [CT], MRI or bone scan)
Study subjects will have undergone or are scheduled for PET-CT and/or bone scan within about 2 weeks of the WB and primary tumor DWI MRI
At least one site of disease outside of the liver that is seen on standard imaging (e.g. CT, bone scan, MRI, FDG PET/CT); patients with measurable or nonmeasurable disease are allowed
Baseline FDG-PET/CT scans must demonstrate at least one hypermetabolic lesion as defined by the Deauville criteria localizing to CT-defined anatomical tumor sites
Each patient must have completed conventional imaging and staging and CT (multiphase) or MRI before initiation of the investigational PET studies
EXPANSION COHORT: Patients must be able to undergo PET scan without sedation
Requirement for sedation for PET/CT scans
5 or more foci of demonstrable metastases on recent imaging modalities (CT, magnetic resonance [MR], fludeoxyglucose [FDG] PET/CT)
Patients who cannot undergo PET/CT scanning
Patients who require sedation for imaging studies will be excluded from the FLT PET scan research test; they will undergo only the standard of care MRI and FDG PET scan
Inability to lie flat for the duration of PET/CT and V/Q SPECT/CT (approximately 45 minutes for each study)
Clinically indicated PET/PET-CT (with or without clinically indicated diagnostic MRI)
Have one or more tumors visualized by conventional PET-CT, CT or magnetic resonance imaging (MRI) prior to the PET FMAU study; PET-CT should be within one week prior to 18F-FMAU
Computed tomography (CT) simulation, immobilization, MRI and PET imaging, treatment planning, and all follow-up MRI and PET scans to be performed at Mayo Clinic Rochester; Note: the actual radiation therapy treatments and follow-up other than imaging can be performed at Mayo Clinic Rochester, Northfield, LaCrosse, Mankato, Eau Claire, or Albert Lea
IF CT CONTRAST AGENTS ARE TO BE USED:
Patients who cannot undergo PET/CT scanning (i.e. because of weight limits, claustrophobia)
Radiologic evidence of new or progressive metastatic disease demonstrated on anatomical imaging (CT, magnetic resonance imaging [MRI], or ultrasound), bone scintigraphy, fluorine F 18 sodium fluoride ([18F]sodium fluoride) PET, and/or fludeoxyglucose F 18 ([18F]FDG) PET
Unable to lie flat during or tolerate PET/CT
Unable to cooperate for MRI and/or PET/CT
Able to cooperate for the PET CT scan when registered on study
Participants will have had, or are scheduled to have clinical imaging evaluations which may include FDG PET CT, or CT, or MRI within 4 weeks of entry
Inclusion Criteria:\n\n        Male or female patients with either:\n\n        Newly diagnosed non small cell lung cancer (NSCLC) (Group A) who meet the following\n        criteria:\n\n          -  Previously untreated, histologically or cytologically confirmed stage IIB, IIIA or\n             IIIB disease, without evidence of distant metastases\n\n          -  A measurable primary tumor with at least one diameter > 2 cm or primary tumor\n             extending to one or more lymph nodes which cannot be distinctively delineated as\n             confirmed by a diagnostic quality chest CT performed within 4 weeks prior to\n             initiation of the concurrent CRT.\n\n          -  Planned to receive concurrent chemoradiotherapy as definitive treatment. The radiation\n             dose should not exceed 70 Gy.\n\n          -  Undergone the following minimum workup to confirm disease staging within 4 weeks prior\n             to initiation of the concurrent CRT:\n\n               -  GBCA-enhanced Brain MRI or contrast enhanced CT if there are signs or symptoms\n                  suggesting brain metastases within the past 2 months.\n\n               -  If necessary to confirm stage of disease, an upper abdomen CT scan will be\n                  performed.\n\n               -  whole-body FDG PET/CT; OR\n\n          -  Newly diagnosed squamous cell carcinoma of the head and neck (SCCHN) (Group B) who\n             meet the following criteria:\n\n               -  Previously untreated, histologically or cytologically confirmed (from the primary\n                  tumor and/or lymph nodes) stage III-IV disease without evidence of distant\n                  metastases.\n\n               -  A measurable (i) primary tumor with at least one diameter ?2 cm and (ii) lymph\n                  node with at least one diameter ? 2 cm as confirmed by a diagnostic quality neck\n                  CT performed within 4 weeks prior to initiation of the concurrent CRT.\n\n               -  Planned to receive concurrent chemoradiotherapy as definitive treatment. The\n                  radiation dose should not exceed 70 Gy.\n\n               -  Have undergone the following minimum workup to confirm disease staging within 4\n                  weeks prior to initiation of the concurrent CRT:\n\n          -  Whole-body FDG PET/CT.\n\n          -  Patients ? 18 years of age.\n\n          -  Able to comply with lying still during the PET/CT imaging session which may last for\n             up to 3 hrs with intermediate breaks.\n\n          -  ECOG performance status of 0, 1 or 2.\n\n          -  Adequate renal function and adequate hepatic function, as assessed by standard\n             laboratory criteria and defined as:\n\n          -  Serum creatinine ? 1.2 times the Upper Limit of Normal (ULN).\n\n          -  Total bilirubin ? 1.5 times the ULN.\n\n          -  Asparagine aminotransferase (AST) and/or alanineaminotransferase (ALT) ? 2.5 times the\n             ULN (grade 1 according to the NCI-CTCAE v.3).\n\n          -  Women of child-bearing potential must have a negative blood pregnancy test at\n             screening and use an adequate and medically acceptable contraceptive method.\n\n          -  Willing and able to comply with the protocol requirements.\n\n          -  Able to provide written informed consent.\n\n        Exclusion Criteria:\n\n        Exclusion criteria specific to patients with NSCLC (Group A):\n\n          -  Predominant small cell carcinoma histology.\n\n          -  Pure bronchioalveolar cell carcinoma histology.\n\n          -  Treatment planned with chemotherapy other than a platinum-based doublet regimen.\n\n          -  Malignant pleural or pericardial effusions.\n\n          -  Any contraindication to perform CT with IV contrast agent.\n\n        Exclusion criteria specific to patients with SCCHN (Group B):\n\n          -  Histology other than squamous cell carcinoma.\n\n          -  Treatment planned with chemotherapy other than a platinum-based regimen.\n\n          -  Treatment planned with cetuximab.\n\n          -  Treatment with induction chemotherapy.\n\n          -  Any contraindication to CT with IV contrast agent.\n\n          -  Evidence of distant metastases.\n\n          -  Patients who, based on the investigator's judgment, have other unstable medical\n             conditions that may preclude safe and complete study participation.\n\n          -  Treatment with any investigational drug, device or biologic agent within 30 days prior\n             to administration of [18F]-ML-10.\n\n          -  Pregnancy or lactation.
Patient may have had a prior PET or PET/CT scan for staging/restaging.
Stage T1-4bN1-2, by the American Joint Committee on Cancer (AJCC) 7th edition, based on the following minimum workup:\r\n* CT chest/abdomen with contrast\r\n* MRI pelvis with contrast\r\n* PET/CT of the whole-body or skull base to mid-thigh
No clinical evidence of nodal disease (N1-N3) as assessed by CT and/or positron emission tomography (PET)/CT
Patients will have undergone or have agreed to undergo standard of care CT of the chest, abdomen, and pelvis; 18F-FSPG PET imaging will be performed as investigational studies
Have undergone or agree to undergo standard of care imaging for ovarian cancer with CT chest, abdomen, and pelvis
Stage T1-4aN1-2, by the American Joint Committee on Cancer (AJCC) 7th edition, based on the following minimum workup:\r\n* Computed tomography (CT) chest/abdomen with contrast \r\n* Positron emission tomography (PET)/CT of the whole-body or skull base to mid-thigh\r\n* Patients must have regional adenopathy and have undergone endoscopic biopsy with endoscopic ultrasound (EUS)-proven peri-esophageal nodal involvement
Patient is able to remain still for duration of imaging procedure (approximately 90 minutes total for PET/CT and PET/MRI)
No evidence of metastatic disease on conventional imaging, including a negative bone scan for skeletal metastasis and negative contrast-enhanced CT
Unable to lie flat, still or tolerate a PET/CT scan
Patients who have received any contrast medium (X-ray, MRI, computed tomography [CT] or ultrasound [US]) in the 24 hours prior to the research US exam
Clinical, laboratory, or diagnostic imaging findings on CT, MRI, and/or 18F-FDG PET/CT
Have one or more breast tumors visualized by conventional PET/CT, CT or magnetic resonance imaging (MRI) prior to the PET FMAU study; PET/CT should be within a week prior to 18-F FMAU
Have one or more breast tumors visualized by conventional PET/CT, CT or MRI prior to the PET FMAU study; PET/CT should be within a week prior to 18-F FMAU
Patients with a known or suspected malignancy who are receiving care from a pediatric oncologist and are already scheduled to receive an outpatient PET/CT examination
Presently planned for restaging using contrast-enhanced computed tomography (CT) scans at baseline and at least every 6 months, as a part of their standard of care assessments
Participant with confirmed head and neck SCC:\r\n* CT and/or MR imaging has been completed within six (6) weeks prior to enrollment, even if the SCC diagnosis has been made via other methods, and will be submitted to American College of Radiology Imaging Network (ACRIN);\r\n* Simultaneous diagnostic CT with PET will not be excluded, but in such cases PET cannot be used as part of the criteria to define the N0 neck as required for entrance to the trial;\r\n* If sites received CT and/or MR images from institutions other than their own, ACRIN recommends a re-read by a local neuroradiologist to ensure compliance with protocol eligibility requirements
Patients starting abiraterone or starting enzalutamide ), within approximately 1-7 days of baseline 18F-DCFPyL PET/CT
Patients who have started radiographic evaluation and underwent CT scan and/or bone scan prior to registration to the study will be able to participate under a late registration provision, provided that the more modern scans (WB/axial MRI and F-18 NaF PET/CT) can be completed within 8 weeks after CT scan and bone scan
Patients must have evaluable disease by CT scan
Able and amenable to baseline and follow-up PET/computed tomography (CT) imaging and study-specific biopsy procedures\r\n* Note: If there are any imaging concerns that the patient may not be suitable for quantitative PET/CT (e.g., a metallic device directly overlies the breast), discussion with the local and central radiologists is required to confirm eligibility for the trial; also, it is expected that subjects have all PET/CT imaging done on pre-qualified machines for the study; if baseline imaging done on another machine, please contact the Protocol Chair/designee for guidance prior to confirming eligibility
OVARIAN CANCER PARTICIPANTS: Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or other study procedures
BREAST CANCER PARTICIPANTS: Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or other study procedures
LOCALIZED RCC TREATED WITH PARTIAL NEPHRECTOMY:\r\nHave primary or suspected diagnosis of RCC, with presence of cT1-2 renal mass by diagnostic computed tomography (CT) assessment
ADVANCED RCC TREATED WITH RADICAL NEPHRECTOMY:\r\nHave pathologic or suspected diagnosis of RCC with presence of cT1-4 renal mass and evidence of nodal or metastatic involvement by diagnostic CT assessment
Patients with endobronchial involvement seen on chest CT
Patients who cannot undergo PET/CT scanning (i.e. because of weight limits, claustrophobia)
PET/MR or PET/CT is not able to be scheduled within 72 hours of radioembolization
Unable to lie flat, still or tolerate a PET scan
Patient’s tumor(s) must be FDG avid on baseline standard of care FDG-PET/CT or PET/MR imaging that was performed at Barnes-Jewish Hospital Clinical PET Facility
If the patient will be scanned on the PET/MR for the mid-treatment scan, they must be determined to be safe for exposure to the magnetic field; this will be determined the day of imaging by the technologist with the use of a screening form; if a patient is not safe for the PET/MR scanner, their mid-treatment images will occur on the PET/CT scanner in the Center for Clinical Imaging Research
Baseline imaging to rule out distant metastatic disease (technetium Tc 99m [99mTc] bone scan, sodium fluoride [NaF] PET, total body MRI, or computed tomography [CT] chest/abdomen/pelvis)
Patients may not have received trastuzumab within 6 weeks of projected 64Cu-DOTA-trastuzumab/PET-CT
Absence of target lesions (> 2.0 cm) on staging CT
Undergone a non-contrast chest CT in a time frame that will accommodate experimental imaging (s-DCT) within 2 weeks
Unable to tolerate 60 min of PET imaging per imaging session
Unable to cooperate for PET/CT
Patients undergoing a planning CT scan in the Department of Radiation Oncology with tumor motion assessment - planning 4-dimensional (4D)-CT ordered by the treating radiation oncologist
Measurable disease (>= 1.5 cm) as assessed by 2 dimensional measurement by computed tomography (CT)
At least 1 measurable site of disease on cross-sectional imaging (CT/PET)
Patients must have disease with FDG-PET/CT avidity
Radioiodine (RAI)-resistant disease as defined by one or more of the following criteria:\r\n* One or more measurable lesions that do not demonstrate RAI uptake\r\n* One or more measurable lesions progressive by RECIST 1.1 =< 14 months of prior RAI therapy\r\n* One or more measurable lesions present after cumulative RAI dose of >= 600 mCi\r\n* One or more measurable lesions that are fludeoxyglucose F-18 (FDG)-avid (> 5 standardized uptake value [SUV]), if positron emission tomography (PET)/CT scan performed; these lesions may also be RAI-avid
Patients who cannot undergo PET/CT scanning (i.e. because of weight limits)
Any contraindications to PET/CT or lymph node mapping (inability to control serum glucose to a value of =< 200 mg/dl for fludeoxyglucose F-18 [FDG]-PET/CT)
Not suitable to undergo CT with an iodinated contrast agent:\r\n* Weight greater than that allowable by the CT table
Participant must be able to complete a PET/CT scan and MRI without the use of sedation
OR a suspected low-grade brain tumor, where confirmation is based upon a combination of other imaging (e.g. PET/CT, MRI, diagnostic CT) and clinical assessment.
All pathology specimens must be within 1 year of the planned 18F-FSPG PET/CT scan.
The time interval between 18F-FSPG PET/CT and other imaging (including other PET/CTs, MRI or diagnostic CT) should be within 4 weeks (exceptions will be allowed for 6 weeks, if there are no other options)
No chemotherapy, radiotherapy, or immune/biologic therapy scheduled or performed between other imaging (PET/CTs, MRI, or diagnostic CTs) and18F-FSPG PET/CT.
Patients must be willing to lie flat on their back in the PET/CT scanner for up to 2 hours to allow the imaging data to be obtained
Diagnosis of extensive stage disease (extensive stage [ES]-SCLC), with stage established by computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) scan
Any biopsy proven HER2-positive malignancy; American Society of Clinical Oncology (ASCO) guidelines will be used to define HER2-positivity for breast cancer; similar guidelines will be used for other cancer types as appropriate; at least one malignant lesion on CT, magnetic resonance (MR), or fludeoxyglucose (FDG) PET/CT within 60 days of protocol enrollment
Patients who cannot undergo PET/CT scanning because of weight limits; PET/CT scanners may not be able to function with patients over 450 pounds
Patients should have no contraindications for FDG-PET/CT
Metastatic workup\r\n* Whole body sodium fluoride (NaF) PET/(CT) computed tomography or 99mTc bone scan
Subjects with advanced disease who have failed hormone therapy and who have sufficient tissue (obtained before or after 20 weeks of Eovist® injection) from a soft tissue or metastatic bone lesion (measuring >= 1.5 cm in diameter at computed tomography [CT] or MRI scan) available for OATP1B3 expression or
Patients that have early stage non-small cell lung cancer or clinical suspicion of the same in cases where the lesion is not amenable to biopsy but is enlarging and positron emission tomography (PET)-positive; all patients are to be treated with stereotactic body radiation therapy as a monotherapy
Pretreatment evaluations required for eligibility include:\r\n* A medical history, physical examination, weight, assessment of ECOG performance status within 4 weeks prior to study entry;\r\n* Evaluation by an experienced thoracic cancer clinician within 8 weeks prior to study entry;\r\n* For women of childbearing potential, a serum or urine pregnancy test must be performed within 72 hours prior to the start of protocol treatment;\r\n* CT scan (preferably with intravenous contrast, unless medically contraindicated) to include the entirety of both lungs, the mediastinum, liver, and adrenal glands; primary tumor dimension will be measured on CT;\r\n* Whole body positron emission tomography (PET)/CT scan using fludeoxyglucose (FDG)-18 with adequate visualization of the primary tumor and draining lymph node basins in the hilar and mediastinal regions; \r\n* Ability to understand and the willingness to sign written informed consent document
Cohort B only:- Presence of at least three distinct metastatic lesions by standard imaging including whole body bone scan + cross-sectional imaging of the abdomen and pelvis obtained within 12 weeks prior to protocol scan
Negative or equivocal findings on standard-of-care imaging for restaging of disease in the previous 60 days consisting of: Whole-body 99mTc bone scintigraphy or NaF PET-CT; and either CT or MRI of the pelvis (or the abdomen and pelvis).
Inability to tolerate 18F-fluciclovine PET/CT
Patients with bone metastases on PET/CT
Patients without bone metastases on PET/CT
Time between the diagnostic CT and PET/CT will be no more than 30 days with no intervening treatment to ensure that any differences found between the exams are related to imaging technique and not a change in disease
Patient will be undergoing a FDG-PET scan as part of staging or response assessment for malignancy; Note: the patient may be newly-diagnosed, currently receiving therapy, or have already completed therapy; the presence of identifiable tumor on the PET scan is not required
Evidence of metastatic disease demonstrated by an abnormal bone scan, CT scan, MRI and/or FDG-PET scan within 6 weeks (with no further interval treatment before imaging trial)
Negative pregnancy test within 7 days of baseline positron emission tomography (PET) scan for pre-menopausal patients
Be a candidate for [18F]FLT PET imaging
Participant is scheduled for standard clinical and/or investigational PET/CT scan or 131 I therapy within the Nuclear Medicine Service at Main Hospital
Radiotherapy, chemotherapy or any investigational agent within the previous 2 weeks of administrating 18F-PEG6-IPQA for PET/CT imaging
A non-investigational targeted agent within the previous 2 weeks of 18F-PEG6-IPQA for PET/CT imaging
Thoracic or abdominal surgery within the previous 2 weeks of 18F-PEG6-IPQA for PET/CT imaging
Patients must be able to lie flat for at least 60 minutes and fit on PET-CT scanner
Radiation treatment to bone less than 4 weeks from the first PET scan
Radiopharmaceutical treatment to bone less than 4 weeks from first PET scan
Radiographic evidence of lymphadenopathy, defined as a lymph node greater than 1 cm in diameter on axial imaging (CT or MRI or positron emission tomography [PET]/CT)
Patients with contraindications for PET/CT or who cannot complete a PET/CT scan
DYNAMIC COHORT: At least one lesion >= 1.0 cm that is seen on standard imaging (e.g. CT, MRI, ultrasound, FDG PET/CT)
Patients must have measurable disease (1.0 cm or greater) by computed tomography (CT) scan
Must be able to tolerate PET/CT (i.e. not claustrophobic and able to remain supine)
Had a chest computed tomography (CT) scan within the past 18 months prior to enrollment
Patients for whom the physician is able to identify suitable implantation sites for the anchored transponders on a recent (within the past 8 weeks) CT scan. This will require acquisition of a CT scan if a suitable one is not already available.
Pelvic and para-aortic lymph nodes must be negative on CT-scan or MRI of the abdomen and pelvis performed within 12 weeks prior to enrollment into the study
No evidence of bone metastases (M0) on bone scan within 120 days prior to registration (PET/CT is an acceptable substitute). Equivocal bone scan findings are allowed if bone CT or MRI of hot spots are negative for metastasis